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ABSTRACT 
PATHOPHYSIOLOGY AND CLINICAL IMPLICATION OF LOWER RESPIRATORY 
TRACT INFECTION (LRTI) WITH RESPIRATORY ENTERIC ORPHAN VIRUS 
(REOVIRUS): BACKGROUND AND EXPERIMENTAL EVIDENCE 
BY MARET E. BERNARD 
Background. Respiratory viral infection early in life is a predominant factor in the 
inception of episodic wheezing and development of asthma amongst young children [1] and a 
serious health challenge. Previous studies of lower respiratory tract infections (LRTI) with 
respiratory syncytial virus (RSV) in animal models have indicated that early life viral exposure 
results in dysregulated neuroimmune interactions and altered synthesis/release of pro-
inflammatory neuropeptides generating increased airway reactivity and neurogenic-
inflammation. Similar to RSV, respiratory enteric orphan virus (Reovirus) is a common 
respiratory pathogen associated with pulmonary infections in children.  Also, reovirus pulmonary 
infection has been shown to induce increased collagen deposition and be associated with the 
pathogenesis of bronchiolitis obliterans with organizing pneumonia (BOOP).  In this study, we 
investigated the effects of reovirus exposure on physiological airway responses and whether 
these responses were associated with neurogenic inflammation and airway remodeling.  
Methods. Adult (12 weeks) and weanling (2 weeks) Fisher-344 (F-344) rats were 
infected with reovirus or a pathogen-free vehicle and the changes in airway vascular 
permeability, neurotrophin expression, inflammatory response and protein content were 
measured at either 5 or 30 days after infection to determine changes in neurogenic inflammation 
and airway remodeling.   
Results. Neurogenic inflammation increased in all treated animals 5 days after 
inoculation and up to 30 days in adult rats. This effect was not associated with any changes in 
nerve growth factor (NGF) and brain-derived neurotrphic factor (BDNF) expression in any 
animals at both time points. All treated animals developed acute pneumonia which resolved at 30 
days. However, weanling rats showed mild peri-alveolar fibrosis at 30 days.  
Conclusions. Reovirus potentiates neurogenic inflammation in rat airways. This effect is 
not associated with changes in neurotrophin expression. In weanling rats, reovirus infection 
induced peri-alveolar fibrosis suggesting that early exposure may carry long-term effects which 
may be clinically relevant. 
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CHAPTER 1 
Respiratory Enteric Orphan Virus  
Introduction 
Respiratory enteric orphan viruses (Reoviruses) [2] are commonly found in the airways 
of exposed infants early in life [3-5] and are associated with pulmonary infections and the 
common cold [6].  Reovirus has been extensively studied as an ideal experimental model of viral 
pneumonia [7], however little is known about the pathologic mechanisms of reovirus-induced 
pulmonary infection. 
Reoviruses were first isolated from healthy children’s stool in 1954 and classified as a 
member of the ECHO type 10 viruses.  It was later determined that the virus had distinctive 
characteristics from other members of the ECHO type 10 group and was officially identified by 
Sabin as a respiratory enteric orphan  on the basis of its repeated isolation from respiratory and 
enteric tracts of asymptomatic and symptomatic children [5].  Common symptoms associated 
with reovirus infection are mild, cold-like respiratory difficulties such as a cough or 
gastrointestinal problems, specifically diarrhea.  Current evidence of other clinical manifestations 
are incomplete and patchy, but have demonstrated that reovirus has a wide range of infectivity, 
but predominantly infects the respiratory and gastrointestinal tract [8].  Long term effects of 
clinical sequelae following viral infection have not been fully elucidated. 
Structure and Replication 
Mammalian reoviruses are nonenveloped, cytoplasmically replicating viruses.  The viral 
structure consists of an outer casing and an internal core.  The outer casing is comprised of two 
concentric protein capsids interspersed with fibrous protein spike extensions that generate an 
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appearance described as icosahedral geometry (Figure 1-C).  The outer capsid surrounds the viral 
core that contains the virus’s genome.  The genome consists of 10 segments of double stranded 
ribonucleic acid (dsRNA) that are grouped into three categories corresponding to their size: L 
(large), M (medium) and S (small) (Figure 1-A). Segments range from 3.9 kbp to 1kbp and each 
segment encodes 1-3 proteins with the S1 gene segment being the only bicistronic gene [9] 
(Figure 2-A).  The S1 gene encodes the viral attachment proteins σ1, σ2 and σ3 that form the 
fibrous spikes that extend from the µ1 protein outer capsid which is encoded by the M2 gene 
[10].  The inner capsid is made up of the µ2 protein encoded on the M2 gene and is the site of 
origin for the viral spikes [11] (Figure 1-C).  The viral core consists of the proteins λ1, λ2 and λ3 
that are responsible for producing the necessary tools for viral replication [12]. 
 
Figure 1 Structure and Maturation of Reovirus 
A) Is a schematic representation of reovirus structure showing the three main components: inner capsid, outer capsid and dsRNA 
genome. (adapted from ViralZone reference [13]).    B) An illustration of the different stages of reovirus disassembly starting 
with the nonenveloped, icosahedaral virion (80nm) composed of an outer protein capsid (σ3 and µ1), an inner protein capsid (σ1) 
and the attachment proteins ( σ 1 and λ2). The outer capsid has an icosahedral T=13 symmetry and the inner capsid has an 
icosahedral T=2.  Removal of σ3/VP7 results in the second viral stage known as infectious subviral particles (ISVPs).  ISVPs are 
then further disassembled to form the core particle (λ1, λ2 and λ3) that produces the tools for viral replication.(adapted from 
ViralZone reference [13]).   
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Reovirus infection is a step wise process where the virion first attaches to the host cell via 
an interaction between the σ1 viral protein and the host cell’s sialic acid and junction adhesion 
molecules (JAM) (Figure 2-B).  Following attachment, the virus undergoes endocytosis and is 
transported in endosomes.  Once inside the endosome virions undergo partial cleavage or are 
progressively uncoated through an acidic pH and cysteine-protease dependent process.  This 
results in virions being converted into infectious sub-viral particles (ISVP) (Figure 1-B & C).  
Conversion to ISVPs requires the removal of the major capsid protein σ3, cleavage of the major 
outer capsid protein μ1 into smaller virion-associated fragments and conformational changes to 
the attachment protein σ1.  Conversion to ISVPs can also occur extracellularly through the action 
of proteolytic enzymes, such as those found in the intestines, and act as the primary infectious 
particle.  In this situation the ISVPs infect cells via endocytosis, but they no longer require 
endosomal acidification for processing (Figure 2-B).  Regardless of their site of initial 
generation, ISVPs are processed further within endosomes to form the non-infectious but 
transcriptionally active core particle.  This transformation requires the removal of the σ1 and 
virion-associated μ1 fragments and is associated with the process of penetration through the 
endosomal membrane by the core particle.  The decisive event in the process is the exposure of 
μ1 residues that interact and initiate fusion of the ISVP with the endosomal membrane, providing 
a method of delivery of core particles into the cytoplasm.  At this point conservative transcription 
of the genome occurs.  The virion RNA is copied by the viral RNA polymerase while still in the 
core.  The dsRNA genome does not function as a messenger RNA (mRNA), making the 
production of mRNA the first initial step of the process.  The mRNA is copied from the negative 
strand template found in the dsRNA within the parental cores during primary transcription.  This 
results in production of numerous capped transcripts of positive strand RNA that are not 
4 
 
polyadenylated. Capped mRNAs leave the core and enter into cytoplasm through channels in the 
λ2 core spike.  The extruded capped mRNAs have two different fates.  Some of the mRNAs are 
translated to form viral proteins and are self-assembled to form the viral capsid and cores 
through a process still not completely understood.  mRNAs that are not transcribed are packaged 
into virions where they act as a template for the negative strand to form a complete dsRNA.  
Progeny virus particles assemble in the cytoplasm 6-7h after infection, forming inclusion bodies 
that can be seen in the infected cell.  Nascent virus particles are released when the infected cell 
undergoes apoptosis and/or  lysis [14]. 
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Figure 2 Genome and Pathogenesis of Reovirus 
A) Reovirus has a segmented dsRNA linear genome that contains 10 segments: L1, L2, L3, M1, M2, M3, S1, S2, S3, S4, coding 
for 12-13 proteins. Segment size is 1,189-3,916 nt and total genome size is 23.5 Kb. (Adapted from ViralZone reference [13]).  
B) Reovirus life cycle: (1) attachment via the interactions between the viral s1 protein and host cell sialic acid and/or JAM 
receptors; (2) receptor-mediated endocytosis induces shedding of σ1 and σ3 proteins; (3) µ1 is cleaved by endocytic proteases 
and exits the endosome; (4) primary transcription occurs within reovirus cores and capped mRNAs are released; (5) primary 
translation of all 10 mRNAs by host ribosomes; (6) viral proteins accumulate in viral factories produced by viral nonstructural 
proteins; (7) new cores assemble; (8) synthesis of minus-strand of viral RNA; (9) secondary transcription occurs within new viral 
cores; (10) secondary translation amplifies viral proteins; (11) complete assembly of outer capsid; (12) release follows cells lysis 
or apoptosis.  An alternate route is the endocytosis of ISVPs.  Reprinted by permission from Macmillan Publishers Ltd: 
Oncogene [15], Copyright 2005, Nature Publishing Group (2010) http://dx.doi.org/10.1038/sj.onc.1209041   
Serotypes 
Currently there are three distinct reovirus serotypes that can be differentiated by testing 
hemagglutination (HA) doses [16] and clinical symptoms.  The original prototype of reovirus is 
the type 1 Lang strain (T1L) that was recovered from healthy children or those suffering from 
mild febrile illness [5].  Type 2 reovirus, referred to as the Jones strain, was isolated from 
children suffering from diarrhea, steatorrheic enteritis or that were healthy subjects [8].  The 
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virus was also isolated from chimpanzees with rhinitis and monkeys suffering from pneumonia. 
Type 3 Dearing strain (T3D) was recovered from children suffering from diarrhea or upper 
respiratory infections [8].  Combined, all three reoviruses demonstrate specific cytopathogenic 
effects that can directly infect all mammals, including humans, and can be found in any area of 
the world.  The vast dispersal and general ease of viral infection make reovirus an important and 
common virus. 
Epidemiology 
Investigations of the prevalence of reovirus exposure and/or infection have revealed a 
high incidence level of viral contact amongst children as well as adults.  The seroprevalence of 
antibodies against reovirus has revealed a high occurrence of seropositivity demonstrating a 
considerable frequency of reovirus exposure.  Further evidence of the frequency of reovirus 
exposure is demonstrated by the fact that 50% of adult sera and 25% of childhood sera from 
patients with respiratory infection are positive for reovirus antibodies [17-18].  In 1962, the 
earliest study of reovirus seroprevalence was conducted by Lerner et al. [19] where 235 sera 
samples were collected randomly from patients whose ages ranged from premature infants to 60 
year old adults.  Results from mothers and their newborn infants demonstrated that antibodies to 
all reovirus serotypes pass freely through the placenta and provided passive immunity to infants 
up until 6 months of age, after which anti-reovirus antibodies dissipate.  Anti-reovirus antibodies 
did not begin to appear again until early childhood with 50% of sera being positive by the age of 
10 years old.  The highest amount of sero-positive sera was found in the age group of 41-60 
years old with more than 80% of the patients testing positive for antibodies to reovirus.  This 
demonstrated that the increase of anti-reovirus antibodies in children after loss of passive 
immunity was gained through reovirus exposure early in childhood.  Collectively, this indicates 
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that reovirus is a common infective agent affecting children.  Additionally, a study done by Leers 
and Rozee [17] looked at the incidence of antibodies to all three reovirus serotypes in children 
ages 1 month to 10 years in an urban setting.  They determined that serotypes 2 and 3 
demonstrated the decline of maternal antibodies described by Lerner et al., but found something 
completely different with the serotype T1L.  They determined that the “pattern for T1L 
antibodies demonstrated a process of active infantile infection during the time of collection.”  
T1L antibodies showed a gradual increase during the first year of life that was then followed by a 
more rapid increase during the early school years, which then plateaus by the age of 10.  Once 
again, this demonstrates that active reovirus infections occur very commonly amongst young 
children. 
In a more recent study, Tai et al [20] collected 273 serum specimens from healthy full-
term infants that were followed until 5 years of age.  Serum was tested for anti-reovirus 
Immunoglobulin (Ig), specifically IgA, IgG and IgM antibodies via indirect enzyme-linked 
immunosorbent assay (ELISA).  They found that 75% of infants 0-3 months of age were positive 
for anti-reovirus antibodies which decreased to 11.1% in 3-6 month old infants and totally 
disappeared to 0% in children 6-12 months old.  Seroprevalence began to rise again with 8.2% of 
children 1-2 years of age being positive for anti-reovirus antibodies.  This percentage increased 
to 32.8% in children ages 4-5 years old and grew to 50% in children ages 5-6 years of age.  
These findings mimicked those of the earlier studies and demonstrated that reovirus infections 
are common during early childhood following the loss of passive immunity.  The high rate of 
reovirus infection among young children, adults and elderly, consistently indicated by 
epidemiological evidence, makes this type of infection even more important regarding its 
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potential relevant impact on the public.  However, the mechanisms behind reovirus pathogenesis 
and their long term effects on airway responses are still not fully elucidated.  
Reovirus & Pulmonary Infections 
 Reovirus pulmonary infection has been documented by numerous studies that have 
clarified the entry, pathogenesis and clearance of reovirus from pulmonary tissue and lymph 
nodes (LN) [6, 21].  Reovirus enters the respiratory tract through pulmonary M cells and spreads 
through the airway and into regional lymph nodes resulting in viral pneumonia [22]. Studies by 
Morin et al. characterized reovirus infection as an ideal model of viral pneumonia [7].  They 
demonstrated that intratracheal inoculation with T1L resulted in a pneumonia characterized by an 
influx of inflammatory cells into the alveolar spaces, resulting in epithelial damage as indicated 
by type II alveolar epithelial cell hyperplasia [7].  The inflammatory cells in the alveolar spaces 
were comprised of neutrophils, mononuclear cells and lymphocytes [23].  Both CD4 and CD8 T 
cells, as well as B cells, make up the lymphocyte population present in both the alveoli and 
interstitium of the lungs [24].  It was determined by Morin and colleagues [7] that reovirus 
replication is necessary for the development of pulmonary inflammation and the development of 
pneumonia.  Viral particles have been isolated from type I alveolar epithelial cells and in 
macrophages suggesting that within these cell types viral replication was occurring.  Viral 
replication in alveolar type I epithelial cells is the primary factor responsible for inducing 
epithelial cell damage and loss resulting in type II cell hyperplasia and increased inflammation 
[7].  Alveolar macrophages are responsible for removing apoptotic tissue and other foreign 
material from alveolar spaces.  Macrophage function provides an ideal means for viral entry into 
the cell and a key factor in reovirus pathogenesis.  Reovirus replication in macrophages could 
alter the host response by interfering with chemokine and cytokine production and lymphocyte 
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activation.  For example, neutrophil chemotactic factors keratinocyte-derived cytokine (KC) and 
macrophage inflammatory protein-2 (MIP-2) produced by macrophages can be altered by 
reovirus exposure, indicating the potential for reovirus influence [25].  This effect is serotype 
specific according to viral protein expression and needs to be further studied.  Therefore, 
inflammation in response to reovirus infection of the lungs is characterized by inflammatory cell 
influx and viral replication in alveolar cells that results in type II cell hyperplasia. 
The immune response to primary infection is associated with the development of both a 
type 1 helper T cell (Th1) and type 2 helper T cell (Th2) response, resulting in the production of a 
humoral and cell mediated immune response.  The Th1 immune response is dependent upon the 
activation of both CD4 and CD8 T cells [26] to produce antiviral cytokines such as interferon-γ 
(IFN-γ) and interleukin-12 (IL-12) inducing cell mediated immunity.  The expression of Th1 
cytokines also affects the humoral immune response by inducing antibody class switching to 
IgG2a [27].  The Th2 immune is characterized by the production of IL-6 and IL-10 that results in 
a humoral immune response resulting in IgG1 antibody production [27]. Therefore, viral 
clearance and immunity is dependent upon both humoral and cell mediated immunity.    
Reovirus and Bronchiolitis Obliterans Organizing 
Pneumonia (BOOP)  
Background 
Bronchiolitic obliterans organizing pneumonia (BOOP) is a term that became prevalent 
in the 1980’s to describe a distinct clinical and pathological airway disorder [28].  BOOP is 
characterized by the presence of connective tissue masses that form plugs within the lumen of 
small airways and can extend in a continuous fashion into alveolar ducts and alveoli, indicative 
of organizing pneumonia [28-29].  The polypoid endobronchial connective tissue masses consist 
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of myxoid fibroblastic tissue as well as granulation tissue [30-31].  The intraluminal polyps have 
a central collection of inflammatory cells made up of histocytes, lymphocytes and plasma cells 
[28].  Analysis of polyp cross sections reveal the prominence of fibroblasts as well as fibrinous 
exudates [32].  Other major features include interstitial mononuclear cell infiltrate that are 
variable in density, chronic inflammation of the alveolar walls indicated by type II cell 
hyperplasia and reactivity, increased presence of foamy cells or macrophages in the alveolar 
spaces and the absence of honeycombing [33-34].  The general architecture of the lung is 
maintained with the polyps representing BOOP lesions.  The BOOP lesions begin as focal 
lesions within the alveoli and terminal bronchioles of the lung and progress bilaterally over time 
[34].  The resulting fibrosis can be described as patchy in appearance.  The alveoli appear normal 
except for the slight thickening of the septa resulting from inflammatory infiltrate and 
prominence of type II cells.  Generally speaking, BOOP results in interstitial scarring as a result 
of inflammatory damage to airway epithelia resulting in fibroblastic interstitial thickening [35].     
The development of BOOP is associated with lung injury due to environmental toxins, 
bacterial infections, viral infections and lung or bone marrow transplantation [29].  BOOP 
development can also be due to unknown etiology or more commonly known as idiopathic 
BOOP.  Treatment for BOOP normally involves the administration of corticosteroids which have 
proven to be effective.  However, some patients experience spontaneous remission of BOOP and 
over one third of patients who have completed corticosteroid treatment still have symptoms and 
evidence of BOOP lesions [36].  This demonstrates that not all BOOP cases respond to steroids 
and can be severe to fatal in some clinical cases [37].  Currently, the cellular and molecular 
mechanisms that mediate the formation and resolution of BOOP lesions have not been fully 
clarified.   
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Animal Model of BOOP 
Respiratory reovirus infection was demonstrated by Bellum et al. [38] as a model of 
BOOP.  They found that CBA/J mice inoculated intranasally with 1×107 pfu of T 1/L reovirus 
demonstrated fibrous cellular plugs of the alveolar ducts characteristic of BOOP.  The formation 
of BOOP lesions was preceded by patchy inflammation of the lungs, with focal inflammation 
consisting of mononuclear cell infiltrate that progressed into condensed fibrous polyps or 
collagenous tissue and foamy macrophages.  These became well developed 3 weeks post 
infection.  This indicated the respiratory reovirus infection can serve as an ideal model for BOOP 
pathogenesis and provide a means to determine the cellular and molecular mechanisms 
mediating disease development.    
Pulmonary Fibrosis 
Pulmonary fibrosis (PF) is an unremitting and progressive interstitial and diffuse 
parenchymal lung disease that affects 128,100 people in the United States and 5 million people 
worldwide [39]. The incidence is on the rise as indicated by the number of diagnoses having 
doubled over the past decade [39].  Roughly 40,000 people die each year due to PF, which is the 
same as that for breast cancer.  With no effective treatments the prognosis for patients with PF is 
grim, with an average life span of 3-5 year after diagnosis [39].  Even though PF is extremely 
prevalent there are no FDA approved treatments or cures, making it one of the few remaining 
untreatable diseases.  Advances in research and unsuccessful therapies over the past decade have 
revealed differing explanations of the pathogenesis of PF.  Early ideas focused on the influence 
of chronic inflammation but immunosuppressive therapies have had limited success.  
Subsequently, the focus has shifted to a mechanism that involves both inflammation and repair, 
stating that the pathogenesis of fibrotic lung disease involves the dysregulation of normal tissue 
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repair mechanisms.  The loss of regulation allows for rampant fibroproliferative responses to 
injury and progressive development of fibrosis. 
Fibrosis is an end result of a series of events that occur after damage to the epithelium 
and/or endothelium that results in abnormal tissue repair [40-42].  Under normal circumstances, 
epithelial repair in the lungs proceeds as demonstrated in figure 3 [43].  At the outset of repair, 
inflammatory mediators are released that activate platelet aggregation, clot formation and the 
formation of a provisional extracellular matrix.  Subsequently, inflammatory processes ensue 
with the production of growth factors, cytokines and chemokines, resulting in the recruitment 
and proliferation of leukocytes that are responsible for the removal of dead tissue and promotion 
of angiogenesis.  Fibroblasts transform into their active form, myofibroblasts, known for their 
expression of α-smooth muscle actin (α-SMA) and their ability to contract.  Myofibroblasts are 
responsible for wound contraction and closure.  The final steps include epithelial and/or 
endothelial cell division and migration to the site in order to replace the damaged tissue.  The 
loss of regulation in these processes results in detrimental accumulation of extracellular matrix 
(ECM) components, specifically the over production of collagen resulting in fibrosis.   
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Figure 3 Epithelial Repair Process and Remodeling 
(1) injury initiates activation of macrophages (M) to activated macrophages (AM) and the subsequent recruitment of immune 
cells, (2) mesenchymal stem cells (MSC), or niche stem cells (NSC).  Soluble factors (S) secreted by immune and non immune 
cells (3) act on epithelial cells and fibroblasts which spread and migrate (4) closing of the wound and re-establishing intact barrier 
function.  TGF-β signalling results in trans-differentiation of epithelial cells to myofibroblasts (MY), the EMT, and the initiation 
of a chronic inflammatory response (5) with further elaboration of ECM.  During resolution (6), immune cells disappear from the 
site of injury, macrophages are deacitivated, cells differentiate, and hyperproliferation is reduced through apoptosis, allowing 
tissue remodelling (7).   American Journal of Physiology. Lung cellular and molecular physiology by Lynn M. Crosby & 
Christopher M. Waters. Copyright 2010 by AMERICAN PHYSIOLOGICAL SOCIETY. Reproduced with permission of 
AMERICAN PHYSIOLOGICAL SOCIETY in the format of a Thesis via Copyright Clearance Center.   
Variation in the amount and profile of cytokines and growth factors secreted during 
injury or inflammation serve as the primary determinants in whether or not repair is abnormal.  
The initiation of abnormal repair and development into fibrosis has been attributed to the 
mediator transforming growth factor -β (TGF-β) [44-46].  It has been shown that TGF-β is able 
to control the ECM transcription via a variety of signaling molecules to induce fibrosis (Figure 
4) [46-48].  Specifically, TGF-β signaling through its receptor and smad-2/3 induces increased α-
SMA expression [40, 49-51].  Alternatively, the extracellular signal-regulated kinase (ERK) 
signaling pathway induces collagen type 1 expression and the c-Jun-N-terminal kinase (JNK) 
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pathway induces fibronectin expression [45].  Therefore, regulation of TGF-β signaling is key in 
controlling the fibrotic process. 
 
Figure 4 Altered Repair Results in Fibrosis 
Epithelial-mesenchymal communication is dysregulated in progressive pulmonary fibrosis with aberrant bidirectional signaling 
between tissue compartments. Inflammatory cells that modulate this process are recruited and activated by secreted products 
from these “resident” cells. Resultant effects on alveolar epithelial cells include increased apoptosis, dysregulated proliferation, 
and ineffective migration. Effects on mesenchymal cells include myofibroblast differentiation, resistance to apoptosis, and 
enhanced extracellular matrix (ECM) secretion. Dysregulation of the repair process leads to persistent mesenchymal cell 
activation that culminates in pulmonary fibrosis. Abbreviations: TGF, transforming growth factor; TNF, tumor necrosis factor; 
PGE2,prostaglandin E2; PDGF, platelet-derived growth factor; reactive oxygen/nitrogen species, ROS/RNS; HGF, hepatocyte 
growth factor; TIMP, tissue inhibitors of matrix metalloproteinases; MMP, matrix metalloproteinase; PAI-1, plasminogen 
activator inhibitor-1; uPA, urokinase-type plasminogen activator.  ANNUAL REVIEW OF MEDICINE by Victor J. Thannickal, 
Galen B. Toews, Eric S.White, Joseph P. Lynch III, and Fernando J. Martinez. Copyright 2001 by ANNUAL REVIEWS, INC.. 
Reproduced with permission of ANNUAL REVIEWS, INC. in the format Dissertation via Copyright Clearance Center. 
There are many different possible and relevant mediators that are involved in repair 
processes that could be responsible for the development of fibrosis.  The key features of airway 
remodeling include: the accumulation and activation of inflammatory cells, a Th2 cell immune 
response phenotype, mesenchymal cell hyperplasia and increased matrix protein deposition as 
shown in figure 4.  This review focuses on the role of caveolin-1 (cav-1) and the eicosanoids in 
the development of fibrosis in relation to airway reovirus infection. 
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CHAPTER 2        
Caveolae: Caveolin-1 (cav-1) 
Introduction 
Caveolae (Latin for “little caves”) are a subset of lipid rafts, which are described as 
highly-ordered microdomains within the plasma membrane [52-53].  They were first identified 
by electron microscopy (EM) examination in the 1950’s by Palade and Yamada, who described 
them as 50-100nm “flask shaped” membrane invaginations or flat pits that are anchored by the 
actin cytoskeleton [54-55] (Figure 5-A).  Other distinguishable features of caveolae include their 
unique lipid profile that are rich in glycosphingolipids, sphingomyelin and cholesterol and by 
their principal protein components known as caveolin [56-59].  Caveolae are found in a vast 
array of terminally differentiated cell types, including endothelial cells, pneumocytes, fibroblasts, 
adipocytes and muscle cells [60-61].   
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Figure 5 Membrane Topology, Domains and Signaling 
A) The electoron micrograph show caveolae in adipocytes that have been surface-labeled with an electron-dense marker. B) (top) 
Schematic demonstrating caveolin inserted into the caveolar membrane, with the N and C termini facing the cytoplasm and the 
‘hairpin’ intramembrane domain embedded within the membrane bilayer. The scaffolding domain has a conserved basic (+) and 
bulky hydrophobic residues (red circles) and the C-terminal domain, which is close to the intramembrane domain, is modified by 
palmitoyl groups that insert into the lipid bilayer. (bottom) The predicted membrane topology of Cav-1 as a dimer and a 
schematic of the cav-1 domains.  Macmillan Publishers Ltd.. Reproduced with permission from Nature Publishing Group in the 
format of a Thesis (2010) via Copyright Clearence center.  C) Regulation of signaling via caveolae microdomains. G-protein–
coupled receptors (GPCR), G-proteins (  and ß ), and receptor tyrosine kinases can reside in or translocate in and out of 
caveolae. Cav-1 directly regulates protein function or indirectly regulates Ras-Stat, extracellular signal-regulated kinases (Erk), 
and Janus kinases (Jak)-Stat signaling pathways. Lipid-modified proteins such as endothelial nitric oxide synthase (eNOS) and 
the Src family of kinases can target to caveolae and interact with caveolin-1. Reproduced with permission from Wolters Kluwer 
Health: Circulation Research [62], copyright 2004. 
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The earliest function of caveolae was deduced based on its membrane location and the 
protein components present in each, which indicated that caveolae, were primarily involved in 
vesicle trafficking [61, 63].  For example, caveolae play a role in clathrin-independent 
endocytosis, transcytosis, potocytosis, cholesterol transportation and calcium metabolism [64-
69].  The early description of caveolae function only describes one of the two purposes of 
caveolae.  The second function of caveolae is to regulate signal transduction, allowing them to be 
regarded as signalosomes [60, 70-71].  More specifically, caveolae serve as signaling platforms 
by compartmentalizing and concentrating various classes of signaling molecules, including G-
protein subunits, receptor and non-receptor tyrosine kinases and other protein components 
(Figure 5-C) [72-76].  In summary, caveolae are involved in a variety of cellular processes 
including endocytosis, lipid homeostasis and signal transduction.  The multifunctional nature of 
caveolae provides a paradigm by which numerous disease processes may be affected, indicating 
the importance of caveolae [77-81]. 
Cav-1 Protein 
The integral membrane proteins, called caveolin, are the principal and indicative protein 
components of caveolar membranes [60].  They are predominantly located at the plasma 
membrane and serve as protein markers of caveolae, but are also found in the Golgi, 
endoplasmic reticulum (ER), in vesicles and at cytosolic locations [52, 82-83].  The caveolin 
gene family consists of three members in vertebrates: caveolin-1, caveolin-2 and caveolin-3, 
which encode four protein isoforms (caveolin-1α, caveoline-1β, caveolin-2 and caveolin-3) [60].   
Caveolin-1, also known as Cav-1 or VIP21, is a 21 to 24 kDa protein that associates with 
the cytoplasmic surface of caveolae.  It was the original member of this family and serves as the 
primary structural component of caveolae [84] (Figure 5-A).  In fact, along with cholesterol and 
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sphingolipids, cav-1 appears to play a direct role in caveolar biogenesis [57, 60, 85].  The two 
other members of the caveolin family, caveolin-2 (cav-2) and caveolin-3 (cav-3), also target 
exclusively the caveolar microdomains [60].  The expression levels of cav-1, -2, and -3 fully 
correlate with the presence of caveolae in those tissues. Interestingly, the expression patterns of 
cav-1 and -2 are largely distinct from that of cav-3; whereas adipocytes, endothelial cells, 
pneumocytes, and fibroblasts have the highest expression levels of cav-1 and -2, cav-3 
expression is limited to muscle cells of all types (cardiac, skeletal, and smooth muscle cells) [52, 
86-87].  The three proteins overlap in their expression in a few cell types, including smooth 
muscle cells. Since their discovery, the caveolin proteins have been shown to be intimately 
involved in all aspects of caveolar function. 
The many functions of caveolae can be attributed to its major protein component, cav-1.  
Cav-1 is able to interact with signaling molecules, scaffolding proteins and different membrane 
components through the different domains found along its structure (Figure 5-B).  The 3 distinct 
structural regions of cav-1 are the hydrophilic cytosolic N-terminal (1-101 residues) and C-
terminal (135-178 residues) regions which flank the central hydrophobic domain(102-134 
residues) creating a hairpin-like structure that spans the plasma membrane [60].  The N-terminal 
and C-terminal are oriented towards the cytosol with the central region located in the membrane.  
The membrane attachment domains are located at the N- and C-termini and are designated as N-
MAD (residues 82-101) and C-MAD (residues 135-150) [88-89].  Located along the c-terminal 
are palmitoylation sites on cysteine (Cys) 133, 143 and 156, that are involved in membrane 
anchorage [90-91]. The central region (residues 102-134) was first suggested to be a 
transmembrane domain (TMD), but after predicting its beta-sheet rather than alpha-helix 
conformation, it was suggested that it was a protein binding domain.  Further analysis indicated 
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that the domain was involved in hetero-oligomerization of cav-1 with cav-2 and in specific 
interactions with other proteins [92]. The caveolin scaffolding domain (CSD), located at the N-
terminus (amino acids 82-101), is involved in the binding and inhibition of proteins containing a 
defined caveolin binding motif, such as ωxxxxωxxω or ωxωxxxxω - where ω is an aromatic 
amino acid (Trp, Phe or Tyr) [93]. The oligomerization domain (amino acids 61-101) contains 
CSD and directs the formation of homooligomers (14-16 cav-1 molecules), which interact with 
cholesterol and signaling molecules [89]. 
The organization of the individual cav-1 domains provides a structural platform for 
recruiting and compartmentalizing signaling proteins (Figure 5-C).  Several signaling proteins 
have been reported to assemble in caveolae and interact with cav-1 such as: receptor tyrosine 
kinases and their downstream associates (Epidermal Growth Factor Receptor (EGFR), Platelet 
Derived Growth Factor Receptor (PDGFR), v-Ha-ras Harvey rat sarcoma viral oncogene 
homolog (H-Ras), V-raf-1 murine leukemia viral oncogene homolog 1 (Raf-1), ERK, 
Phosphatidylinositol 3-kinases (PI3K)) [94-100], non-receptor tyrosine kinases (Src family, Fak) 
[99, 101], receptor serine/threonine kinases (TGF-β receptor type I) [102-103], G-protein 
coupled receptors and their downstream associates (G-protein alpha subunits, adenylyl cyclase, 
Protein Kinase-A (PKA), PKC isoforms) [104-108], steroid hormone receptors (Androgen 
Receptors (AR) and Estrogen Receptors (EstR)) [109-111], Endothelial nitric oxide synthase 
(eNOS) [112-114] and numerous others.  Cav-1 binding acts as a negative regulator upon most 
signaling molecules.   For example, as a tumor suppressor, cav-1 binds to EGFR and inhibits 
phosphorylation and activation of the receptor.  Cav-1 also is able inhibit activation by binding 
directly to signaling molecules and stopping signaling cascades.   
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Cav-1 and Inflammation 
The involvement of cav-1 in the processes of inflammation is multifaceted and is 
indicative of its varied functions as a membrane protein.  The expression of cav-1 by immune 
cells is not well defined due to varying results from different cell lines.  Previous research 
suggests that it is expressed by myeloid, but not lymphoid cells, but due to more specific and 
elaborate detection methods, recent evidence suggests that it is present in all immune cells.  Cav-
1 has been identified in murine macrophages [115] and mast cells [116], human dendritic cells 
[117], mast cells (MCs) [116], lymphocytes [85] and neutrophils (PMNs) [118] and bovine 
monocytes, macrophages and dendritic cells (DCs) [119].  Cav-1 expression in these cells is not 
isolated to the cell surface, but can be present intracellularly as in the case of bovine DCs where 
cav-1 is focally isolated to the perinuclear region.   Expression may also not be constitutive but 
inducible by different signals, making it difficult to determine the expression.  This is the case 
with peritoneal macrophages, which demonstrate sparse caveolin staining concentrated in 
vesicles in the golgi region.  Subsequent stimulation with Freund’s adjuvant results in increased 
caveolin staining that is no longer restricted to the golgi, but dispersed throughout the 
macrophage.  Murine macrophages demonstrated similar increases in cav-1 post exposure to 
lipopolysaccharide (LPS).  Therefore, cav-1 expression may not be constitutive, but rather 
transient and stimulus specific.  The nature of cav-1 expression amongst immune cells is 
dependent on different factors including cell type and state of activation, indicating that cav-1 
could be an important component in mediating specific immune cell functions.  It has been 
demonstrated that cav-1 plays a part in regulating PMN, macrophage, antigen presenting cell 
(APC), B cell and T cell functions.   
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The presence and function of cav-1 in PMNs is incompletely understood.  Studies have 
indicated that cav-1 is important in the mechanism of PMN activation, adhesion and 
transmigration [120].  PMN activation induces the formation of the primary source of oxygen 
derived reactive species, superoxide.  Hu et al. [120] observed that the production of superoxide 
in response to stimulus with PMN activating factors formyl-Met-Leu-Phe (fMLP) plus platelet-
activating factor (PAF) is reduced by 50-80% in cav-1-/- PMNs compared to control, indicating 
cav-1 mediates PMN activation.  Furthermore, cav-1-/- PMN migration and adhesion to 
fibrinogen in response fMLP is reduced compared to controls.  Similarly, both Hu et al. [120] 
and Garrean et al. [121] observed that activated cav-1-/- PMNs exhibited deficient adherence and 
migration to and across pulmonary micro vascular endothelial cell monolayers compared to 
controls.  Combined, this indicates that cav-1 is essential for PMN adhesion and migration. 
Macrophages are one of the primary host immune defense cells, playing an essential role 
in phagocytosis, cytokine production and antigen presentation.  Cav-1 has been shown to be an 
important regulator of macrophages during inflammation, regulating macrophage apoptosis 
[122], lipid metabolism [123], endocytosis [124] and immunomodulatory effects [125].  The role 
of cav-1 in macrophage apoptosis was elucidated by studies using thioglycollate-elicited mouse 
peritoneal macrophages (tg-MPM).  tgMPMs treated with different apoptotic agents, including 
simvastatin, camptothecin or glucose deprivation, resulted in large increases of cav-1 expression 
[122].  Cav-1 increase was determined to be a specific marker of apoptosis that is closely 
associated with the externalization of phosphatidylserine (PS) [122].  Cav-2 did not show similar 
changes in response to the apoptotic agents, indicating this was specific to cav-1.   
Cav-1 is important in mediating macrophage lipid metabolism [123].  Specific 
characteristics of cav-1, such as its ability to bind to cholesterol and it location in cholesterol rich 
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lipid rafts, imply its involvement in the maintenance of cellular cholesterol homeostasis or 
cholesterol efflux.  Specifically, caveolae and cav-1 are associated with the proteins CD36 and 
SR-BI, two members of the B scavenger receptor family that are responsible for high density 
lipid (HDL) transfer.  Studies have shown that cav-1 regulates the activity of both receptors, 
altering cholesterol efflux [123].   
The relationship between cav-1 and macrophages is mainly focused on uptake of antigen 
since cav-1 is essential for non-clathrin coated endocytosis [126-127].  Cav-1 deficient 
macrophages demonstrated impaired phagocytosis that was determined to be dependent upon 
cav-1 expression [124].  Also, treatment with the caveolae inhibitor filipin decreased the speed of 
fluid phase and receptor mediated endocytosis by macrophages[127].  Combined, these two 
studies indicate the importance of cav-1 in phagocytosis by macrophages.       
Cav-1 has been shown to be a potent immunomodulatory molecule in macrophages.  
Macrophage expression of cav-1 is not consistent for all subtypes, but is dependent upon their 
location, environmental signals and function.  Recently, it was verified that cav-1 is expressed by 
peritoneal macrophages (PMs) by Kiss et al. [128].  It was also reported that cav-1 expression by 
PMs is intimately involved in the processes of inflammation and pathogenesis of atherosclerosis 
[123].  Similar to PM, the expression of cav-1 in alveolar macrophages (AMs) was undetermined 
until recently when Wang et al [125] observed cav-1 expression in murine AMs by western 
blotting and immunofluoresence microscopy.  The importance of cav-1 expression by AMs and 
PMs was determined by loss of function analysis using small interfering RNA (siRNA) to down 
regulate cav-1 expression.  Down regulation of cav-1 increased PM and AM inflammatory 
response to LPS stimulation, with increased tumor necrosis factor-α (TNF-α) and IL-6 
production.  However, it also decreased the production of the anti-inflammatory mediator IL-10.  
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Furthermore, over expression of cav-1 in a murine macrophage cell line demonstrated a 
significant attenuation of the proinflammatory cytokine TNF-α and IL-6, and increased IL-10 
production in response to LPS stimulus.  Combined, these results indicate that cav-1 has a 
protective role in inflammation by suppression of proinflammatory cytokine (TNF-α and IL-6) 
production and augmentation of anti-inflammatory cytokine (IL-10) production in response to 
LPS. 
Results from studies of cav-1 and the adaptive immune response has provided evidence 
that cav-1 regulates both T cell and B cell activity.  A study by Ohnumua et al. [129] showed that 
cav-1 is the co stimulatory ligand for CD26, and that interaction/ligation by cav-1 results in T 
cell proliferation and activation with co stimulation from T cell Receptor (TCR)/CD3.  Similarly, 
cav-1 has been shown to influence B cell development of thymus independent immune responses 
[130].  Studies of cav-1-/- mice’s humoral response to thymus dependent and independent 
antigens demonstrated decreased immunoglobulin production in response to thymus independent 
antigen.  This demonstrated that cav-1 deficient mice are unable to develop a normal thymus 
independent immune response, implicating that B cell thymus independent immunity is regulated 
by cav-1.  Therefore, cav-1 plays an integral part in regulating aspects of the adaptive immune 
response. 
Cav-1 serves as a central molecule in signaling cascades allowing it to regulate multiple 
signaling pathways.  Functioning as a scaffolding protein, cav-1 organizes and concentrates 
various classes of signaling molecules, including G protein subunits, receptor and non-receptor 
tyrosine kinases and small GTPases within caveolae.  Moreover, cav-1 also inhibits the 
activation of downstream signaling events of many proteins, including c-Src, H-Ras, mitogen 
activated protein (MAP) kinases.  The primary example of cav-1 regulation of inflammatory 
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signaling is the interaction between cav-1 and nitric oxide (NO) production.  Cav-1 inhibition of 
eNOS regulates inflammatory signaling by decreasing NO production which inhibits the 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
synthesis of proinflammatory proteins [121].   Another important inflammatory signaling 
mediator, cyclooxygenase-2 (Cox-2), has recently been reported to be regulated by cav-1, but by 
a different molecular mechanism [131].  In the ER, soluble cav-1 binds to Cox-2 and facilitates 
its degradation, suppressing Cox-2 mediated proinflammatory activation.  Combined these two 
examples demonstrate that cav-1 is a critical regulator of inflammatory signaling cascades and 
key in the processes of inflammation. 
Cav-1 and Fibrosis 
There is extensive evidence associating cav-1 with the regulation of collagen expression 
in vitro and in vivo.  Experimental models of fibrosis show evidence of decreased cav-1 
expression compared to controls.  A good example is the decrease of cav-1 expression in 
bleomycin-induced fibrosis tissue as well as in cell cultures [132].  Wang et al. observed a 
twofold reduction in cav-1 mRNA in IPF lung tissues compared to control [133].  Cav-1 protein 
expression in idiopathic pulmonary fibrosis (IPF) lung tissue was decreased by 73% when 
compared to controls [133].  The association between reduced cav-1 expression and collagen 
over expression in fibrotic tissue is further substantiated by the fibrotic phenotype seen in cav-1 
knockout mice [134-135].  It is apparent that cav-1 and collagen expression are inversely related 
indicating that cav-1 works in opposition of profibrogenic processes.  Profibrogenic processes 
are regulated by several mediators, such as Th2 cytokines and TGF-β, and different cell types, 
specifically myofibroblasts.  Each of these mediators and cell types are regulated by cav-1 and 
are fundamental in understanding the pathogenesis of fibrosis. 
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Cav-1 serves as a signaling platform for numerous signaling molecules.  The interaction 
of kinases with cav-1 inhibits their activity and therefore prevents profibrotic signaling.  A 
primary example is cav-1 suppression of TGF-β profibrotic signaling (Figure 6).  The regulation 
of TGF-β signaling involves numerous signaling pathways allowing for different methods to 
inhibit activation.  TGF-β SMAD2/3 phosphorylation and nuclear translocation is responsible for 
activating fibroblast α-SMA expression, fibronectin production and collagen type I production.  
The TGF-β receptors (TGF-βRs) I and II are localized in cav-1 enriched fractions of human 
endothelial cells and have been reported to interact by immunopercipitation.  The interaction 
between cav-1 and TGF-βRI was reported by Razani et al. to inhibit smad-2 phosphorylation, 
preventing the smad complex formation and nuclear translocation in fibroblasts [102].  TGF-β 
induced ERK1/2 signaling regulates collagen type I production [45].  ERK1/2 have been 
demonstrated by Mineo et al. [136] to localize to caveolae and directly interact with cav-1.  
Interaction between cav-1 and ERK1/2 inhibits collagen type 1 production.  JNK activation is 
pivotal for TGF-β induced fibronectin production and is regulated by cav-1 via modulation of 
SMAD2 phosphorylation and nuclear translocation.  Therefore, cav-1 regulates TGF-β 
profibrotic signaling by suppressing each signaling cascade and preventing profibrotic signals.   
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Figure 6 TGF-β Profibrogenic Signaling 
A) Diagram that illustrates fibrogenic TGF-β signaling pathways.   After TGF-β binding, Type II receptors (TβR-II), which are 
constitutively active serine–threonine kinases, recruit and dimerize with type I receptors (TβR-I).  Subsequently, TβR-II 
phosphorylates the TβR-I, resulting in their activation. Active TβR-I specifically phosphorylates receptor-regulated Smad2 and 
Smad3 via the protein kinase ALK-5. Phosphorylated Smad 2 and Smad 3 then complex with co-Smad4, resulting in their 
transport to the nucleus.   In the nucleus, they cooperate with other factors to regulate transcription of critical genes, here 
represented by genes encoding CTGF and α1 and α2 type I collagens. B) After TGF-β binding, Type II receptors (TβR-II), which 
are constitutively active serine–threonine kinases, recruit and dimerize with type I receptors (TβR-I).  Subsequently, TβR-II 
phosphorylates the TβR-I, resulting in their activation. TβR-I results in activation of the Ras-Raf-Erk signaling pathway which 
culminates in the production of type-1 collagen.     
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CHAPTER 3 
Eicosanoids 
Introduction 
The eicosanoid family of lipids are integral mediators of inflammation and homeostasis 
that are derived from a single membrane released 20 carbon fatty acid, arachidonic acid [137].  
These lipid mediators have numerous functions that include roles in inflammation, fever, 
regulation of blood pressure, blood clotting, immune system modulation, control of reproductive 
processes, tissue growth and regulation of sleep/wake cycle [138].  Members of the eicosanoid 
family include prostaglandins (PGs), leukotrienes (LTs), prostacyclins, thromboxanes (TXA2) 
and epoxyeicosatrienoic acids (EETs).  They can be classified by their biological activity into 
two categories; those that promote inflammation (pro-inflammatory) and tissue destruction and 
those that stop inflammation (anti-inflammatory) and promote tissue repair [137].  The synthesis 
and degradation of the eicosanoids is tightly regulated to allow the proper balance of damage and 
repair and to prevent an imbalance or disease resulting from either chronic inflammation or 
abnormal fibropriliferation [139].  Therefore, the interaction and balance between eicosanoids is 
critical to homeostasis and could provide insight into the pathology of inflammatory and fibrotic 
disease.  
The pathobiology of pulmonary fibrosis can be attributed to the aberrant 
fibroproliferative response to lung injury resulting from the loss of regulation over tissue repair 
processes.  This results in the remodeling of the airway that is characterized by the loss of 
alveolar epithelial cells that are replaced by excessive deposition of matrix proteins such as 
collagen.  Eicosanoids regulate the cells and pathways involved in the inflammatory response 
and tissue repair and play a significant role in the pathology of lung fibrosis.  PGS and LTs are 
28 
 
the two eicosanoid metabolites whose biological activity has been implicated in the pathology of 
lung fibrosis [140].  Increased levels of LTs and decreased levels of PGs are a characteristic of 
profibrotic milieus.  Studies have indicated that LTs , specifically cysteinyl leukotrienes 
(cysLTs), promote predominantly proinflammatory and fibroproliferative activity, while PGs 
predominantly do the opposite [139].  This review will focus on PGs and LTs and their role in 
pulmonary fibrosis. 
Initiation of Synthesis:  
The initiating step in the synthesis of eicosanoids is the release of arachidonic acid from 
membrane phospholipids by cytosolic phospholipase A2 (cPLA2).  Arachidonic acid is stored in 
abundance as an esterfied component of the phospholipid bilayer  and whose release is tightly 
regulated by the activity of type IV cPLA2 [141].  Optimal functional activation of this enzyme 
requires intracellular calcium flux and phosphorylation by mitogen-activated protein kinases 
(MAPKs) which is inhibited by anti-inflammatory signaling such as corticosteroids and Aspirin 
[142].  Thus, the onset of an inflammatory response is associated with a surge in production of 
these lipid mediators.  Cells are activated by mechanical trauma or by specific cytokines, growth 
factors or other stimuli such as the inflammatory signal platelet activating factor or bradykinin.  
Stimulus results in the activation and translocation of cPLA2 to the nuclear envelope, ER and 
golgi apparatus [143].  Once activated cPLA2 hydrolyzes the ester linkage between a fatty acid 
and the OH at the C2 of the glycerol backbone, releasing inositol trisphosphate (IP3) and 
diacylglycerol which is then catalyzed by diacylglycerol lipase into arachidonic acid.  Free 
arachidonic acid can then be metabolized into any eicosanoid lipid mediators based on the 
abundance and activity of the specific synthetic enzymes. 
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Prostaglandins (PGs) Synthesis  
Cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2), more correctly termed 
prostaglandin endoperoxide H synthases-1 and -2 (PGHS-1 and PGHS-2), are key enzymes that 
catalyze the first committed step in the synthesis of PGS from fatty acid precursors [144] (Figure 
7). COX-1 is always present in tissues and is responsible for basal and constitutive PG synthesis, 
while COX-2 is induced by appropriate physiological stimuli (cytokines, tumor promoters and 
growth factors) in various inflammatory or “induced” settings [145-146].  At the ER and nuclear 
membrane arachidonic acid is presented to COX-1/COX-2 and is metabolized to the intermediate 
prostaglandin H2 ( PGH2).   A range of PGs are generated by conversion of PGH2 by specific 
terminal synthases that are cell- and tissue-specific.    
 
Figure 7 Eicosanoid Synthesis 
Cytosolic phospholipase A2 (cPLA2) releases arachidonic acid from the membrane phospholipids that is metabolized by either 5-
lipoxygenase (5-LO) to initiate the production of the leukotrienes or by cycloxygenase -1 /-2 to initiate the production of the 
prostaglandins.  The synthesis of specific eicoasnoids is carried out by terminal synthases. 
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The pairing of PGH2 synthesis and production of downstream PGs by downstream 
enzymes and specific cell types is the primary means of regulating the production of each 
mediator.  PGE2, PGI2, PGD2, PGF2α and TXA2 are synthesized by both leukocytes and 
structural cells and effect these cells and local tissue.  Generally speaking, PGF2α synthase is 
mainly found in the uterus, prostacyclin synthase is dominantly located in endothelial cells and 
two types of PGD synthase are found in the brain and mast cells.  Looking more specifically at 
the lungs, there are two PGs that are dominantly involved: PGE2 and PGI2.  PGE2 is the most 
ubiquitous and abundant PG with both proinflammatory and anti-inflammatory functions 
dependent on context.   PGE2 can be produced by most cell types that express cytosolic PGE2 
synthase.  More specialized cells, such as macrophages and bronchial epithelial cells express 
microsomal PGE synthase-1 (mPGES-1) and microsomal PGE synthase -2 (mPGES-2) [147].  
mPGES are members of the microsome-assocaited proteins involved in eicosanoid and 
glutathione metabolism (MAPEG)  that also include other enzymes involved in eicosanoid 
synthesis [148].  The expression of mPGES-1 and -2 is up regulated by the same signals 
associated with up regulation of COX-2, indicating their activity is associated with increases in 
inflammation.   PGI2 is synthesized from PGH2 by PGI synthase (PGIS) which is expressed by 
endothelial cells as well as vascular and smooth muscle cells of the airway.  It is highly 
transcribed in the heart, lungs, smooth muscle, kidneys and ovaries.  It is easy to see that 
coordinate induction of multiple enzymes in the prostanoid pathway, in particular mPGES and 
COX-2, can be modified in accordance with the requirements of context to produce the 
appropriate PG response.  The intricate interaction between these mediators is complex and can 
lead to the amplification or dampening of an inflammatory response and the nature of subsequent 
responses.   
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Mechanism of PG Signaling: Receptors and Cellular 
Effects 
PGs are mainly released through facilitated transport via the PG transporter (PGT) to 
interact with local cell types and tissues expressing the appropriate 7 transmembrane G protein 
coupled receptors (GPCR).  There are at least 9 known PG receptors found in both mouse and 
man, along with numerous splice variants (Figure 8).  To be more specific there are four specific 
GPCRs: EP1, EP2, EP3 and EP4 that bind PGE2, two bind PGD: DP1 and DP2 [149-152].  The PG 
receptors are classified into three groups among the GPCR super family based on homology and 
signaling attributes, with DP2 being the only exception.  DP1, EP2, and EP4 are considered “the 
relaxant” receptors.  This group signals through Gs mediated increases in cyclic adenosine 
monophosphate (cAMP) and induce muscle relaxation and vasodilation [137].  Another group, 
known as the “contractile” receptors includes EP1 and signal through Gq mediated increases in 
intracellular calcium leading muscle contraction and vasoconstriction [137].  The EP3 receptor is 
considered an “inhibitory” receptor and signals through Gi mediated decreases in cAMP and has 
been known to induce fever [137].    These receptors are predominantly located at the plasma 
membrane in sites adjacent to PG synthesis where they can induce specific biological effects 
shown in figure 9.   
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Figure 8 LT and PG Receptors 
A) Schematic representation of  a 7-transmembrane g protein coupled receptor. B) Table describing the Leukotriene receptors’ 
ligand specificity and biological effects. C)Table describing the Prostaglandin receptors’ biological effects and signaling 
mechanisms. 
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Figure 9 PG Activity 
A schematic presentation of prostaglandin synthesis, secretion, receptor binding and biological activity.  Upon synthesis 
prostaglandins can undergo facilitated transport from the cell through the prostaglandin transporter (PGT) or other carrier to exert 
autocrine or paracrine actions on a family of prostaglandin receptors EP1, EP2, EP3, EP4, DP1, DP2, and TPα, on the cell types 
indicated. Only a few of the diverse activities of prostaglandins are shown here.   
The Role of PGs in Lung Inflammation 
PGE2 and Its Receptors 
PGE2 is one of the best known and well studied PG, whose diverse regulatory actions 
demonstrate the dual nature of this group.  PGE2 influences almost every cell type involved in 
inflammation by acting through specific EP receptors to induce a particular response.  The 
response to PGE2 is dependent upon which receptor is predominantly expressed; indicating that 
the diverse effects of PGE2 are not specific to the mediator itself, but rather is determined by the 
receptor.  This allows for a single mediator to induce numerous sundry responses in one local 
area in order to produce a specific inflammatory context.   
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The effects of PGE2 on individual cells of the immune system are distinct and contingent 
upon the function and location of the immune cell and its context, whether it is involved in the 
innate or adaptive wing of the immune response.  This can be demonstrated by the varied effects 
of PGE2 signaling on different innate inflammatory cells such as mast cells (MCs).  MCs have 
been shown to be crucial for optimal immune responses during infection because of their ability 
to instantly release several pro-inflammatory mediators from intracellular stores and their 
location at the host–environment interface during the innate response.   They exert these effects 
by altering the inflammatory environment after detection of a pathogen and by mobilizing 
various immune cells to the site of infection and to draining lymph nodes. Studies have 
demonstrated that PGE2 acts as both an inducer and suppressor of MC activation by blocking the 
high affinity Fc receptor for IgE (FcεRI) [153-154].  FcεRI is a member of the multi chain 
immune recognition receptor family that is expressed on the cell surface of macrophages, as well 
as basophils, eosinophils and MCs.  Cross-linking of FcεRI via IgE bound multivalent antigens 
leads to the induction of a signaling cascade that regulates the rapid release of preformed 
mediators such as histamine and heparin (‘degranulation’), the rapid synthesis of arachidonic 
acid metabolites, such as prostaglandins and leukotrienes, and the expression of cytokines (e.g. 
IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, TNF-α) and chemokines [155-157].  Inhibition of FcεRI by 
PGE2 in MCs is attributed to high levels of cAMP and has been shown to stop exocytosis of 
granules, inhibit LTC4 and PGD2 generation and suppress TNF-α.  Specifically, signaling by 
PGE2 through the cAMP mediated EP2 receptor has been shown to block the activity of the high 
affinity FcεRI [158-160].  This results in the suppression of FcεRI mediated exocytosis and 
eicosanoid production.  In contrast, PGE2 signaling through EP3 induces exocytosis and 
eicosanoid generation [159].   The suppressive effects of PGE2 on FcεRI also effects MC 
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transcription of TNF-α by inhibiting FcεRI mediated production through the expression of the 
protein inducible cAMP early repressor (ICER), that can then inhibit cytokine transcription 
[161].  Therefore, PGE2 has the ability to regulate the activation and function of MCs, which in 
turn can directly determine the outcome of an inflammatory response.   
PGE2 is involved in the adaptive immune response as implicated by the expression of the 
EP receptors on T cell, B cells and DCs.  The initiation of the adaptive immune response is 
dependent upon the activation of APCs, specifically DCs.  DCs serve as the source of stimulus 
for other inflammatory cells as a producer of cytokines and as a source of antigenic material for 
lymphocyte activation.  In order to fulfill their function, DCs must be able to take up antigenic 
material and migrate to local lymph nodes to present it to lymphocytes for proper activation and 
response.  PGE2 has been shown to affect all aspects of DC function including activation, 
migration and co-stimulation of lymphocytes.  The activation of DCs is augmented by PGE2 via 
the EP receptors.  The secretion of the cytokines IL-12, CCL3, CCL4, tumor necrosis factor and 
IL-1 is abated in the presence of PGE2 during DC activation [162-165].  Under these same 
circumstances, DCs showed enhanced expression of chemokine receptors, such as CCR7 
necessary for migration to lymph nodes [166].  The presence of PGE2 during DC maturation is 
essential for the acquirement of a migratory phenotype, as demonstrated by a lack of migration 
when PGE2 is not present from the onset of maturation [166].  Early in vivo studies using a 
transgenic mouse lacking the EP4 receptor demonstrated deficient recruitment of Langerhans 
cells [167].  In addition, the inhibition of EP2 and EP4 receptor signaling by antagonists 
demonstrated similar deficiencies in migration [167].  Consequently, agonists for EP2 or EP4 
receptors are able to trigger DC migration, with both receptors being equally apt at facilitating 
migration [162, 166].  Upon migrating to the lymph node, DCs are responsible for activating 
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naïve and memory T cells, and therefore initiate the adaptive immune response.  Studies using 
monocytes derived DCs (MoDCs) isolated from human blood demonstrated that PGE2 matured 
MoDCs have an enhanced potential to induced antigen-specific T cell proliferation.  The co 
stimulatory molecules OX40L and CD70 expression on MoDCs is dependent on PGE2 
stimulation [168].  These co stimulatory molecules induce proliferation of antigen-specific T 
cells when expressed by activated DCs during the adaptive immune response.  Therefore, PGE2 
enhances the proliferation of antigen specific T cells during the adaptive immune response by up 
regulation the co stimulatory molecules OX40L and CD70 [168].   
PGE2 has been shown to regulate the proliferation, apoptosis and cytokine secretion of T-
cells [169].  Studies have mainly focused on CD4+ T-cells and have implicated that PGE2 has 
varied effects on their function and activation.  The inhibition of T-cell proliferation by PGE2 is 
well established, but the mechanism of inhibition is still up for debate.  PGE2 has been found to 
inhibit intracellular calcium release and the activity of p59 (fyn) protein tyrosine kinase; both 
could be the reason for decreased proliferation.  EP receptors are also capable of inhibiting T-cell 
proliferation [170].  Studies have demonstrated that up regulation of certain EP receptors, EP4, 
induce a decrease in the secretion of IL-2 and therefore suppress T-cell proliferation [171]. 
PGE2 not only controls the proliferation of T-cells, it also regulates their survival, directly 
controlling the number and population of T cells present.  PGE2’s modulation of apoptosis is 
dependent upon the age and activation of the T cells.  Naïve CD4+CD8+ double positive 
thymocytes undergo apoptosis in vitro and in vivo when in the presence of PGE2 [172], as do 
resting mature T-cells by increased expression of the protein c-myc [173].  On the contrary, 
PGE2 is able to prevent T cell receptor (TCR)-mediated activation-induced cell death by 
augmenting Fas ligand (FasL) expression on the T-cell surface[174].  Inhibition of T cell 
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apoptosis by PGE2 is also mediated by decreased FasL mRNA and protein expression [174].  
Therefore, PGE2 is selectively induces apoptosis in immature thymocytes, allowing it to play a 
role in the shaping of the T-cell repertoire. Furthermore, PGE2 regulates the activities of mature 
resting and activated T cells respectively, by inducing and inhibiting apoptosis,. 
The influence of PGE2 on the adaptive immune response begins at the point of initiation 
with its ability to regulate dendritic cells whose activity controls the T cell adaptive immune 
response.  The adaptive response can be type 1 or type 2 and is determined by the type of antigen 
present.  The three effector Th subsets involved are Th1, Th2 and T helper 17 cells (Th17) with 
specific cytokines inducing the differentiation of each.  Th1 cell differentiation is induced by IL-
12, Th2 cell differentiation requires IL-4 and Th17 differentiation is induced by TGF-β and IL-6 
and is expanded by IL-23.  PGE2 modulates both DC and T cell cytokine secretion that is 
involved in T helper cell differentiation [168], indicating PGE2 as a plausible regulator of the T 
cell phenotype in the adaptive immune response .  Studies have shown that PGE2 decreases IFN-
γ and IL-2 secretion by T cells, as well as DC secretion of IL-12, TNF and IL-1 [169].  However, 
PGE2 facilitates the expression of IL-23 by activated DCs [175].  Notably, IL-12 and IL-23 share 
the common p40 subunit as well as being responsible for Thcell differentiation.  Combined, the 
ability of PGE2 to abate IL-12 production, while enhancing IL-23 production by DCs, directs the 
adaptive immune response towards a Th17cell phenotype [176].   
PGD2 and Its Receptors 
PGD2 is the major PG produced by the COX pathway in activated mast cells which 
initiates IgE-mediated Type I acute allergic response [177-179].  It is released into the airway 
following antigen challenge by its major cellular source, mast cells, but is also produced by 
inflammatory cells, such as antigen presenting dendritic cells and Th2 cells, as well as 
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fibroblasts, bronchial smooth muscle cells and airway epithelial cells [180-181].  Secretion of 
PGD2 elicits key components of allergic asthma such as bronchoconstriction and airway 
eosinophil infiltration by inducing vasodilatation and increased permeability in order to facilitate 
transendothelial migration of inflammatory cells [182-183].  Other function of this lipid mediator 
includes regulating the activation and chemotaxis of eosinophils, basophils and Th2 cells [149-
150, 184-185].  
In order to exert its biological effects, PGD2 must bind and activate two distinct GPCRs, 
the D prostanoid (DP) receptor and the recently discovered CRTH2 receptor (“DP2”).  The DP 
receptor is a member of prostanoid GPCR super family and signals to Gs-mediated increases in 
intracellular cAMP.  This promotes relaxation of both vascular and airway smooth muscle, 
inducing vasodilation and vascular permeability, promoting extravasation and infiltration of 
inflammatory cells.  Despite avid interest there has not been an established connection between 
DP receptor activation and PGD2 –stimulated eosinophil activation and migration [186-187]. The 
identification of the novel receptor, CRTH2, has provided clarification of the mechanism behind 
PGD2 biological activity [149, 188].  CRTH2 is considered an orphan receptor that is 
predominantly expressed on type 2 polarized lymphocytes [149].  Though DP and CRTH2 
receptors exhibit equivalent binding affinity for PGD2, they share no similarities and are not 
structurally related.  Rather, CRTH2 is most closely related to other chemoattractant receptors.  
The effects of CRTH2 are mediated through Gi-dependent increases in intracellular calcium 
levels and reduction in intracellular cAMP levels, indicative of proinflammatory signaling [149, 
189].  These pathways have been shown to mediate eosinophil activation by regulating the cells 
shape change, actin polymerization and CD11b up regulation [150, 190].  Therefore, the 
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combination of these two receptors help to create an inflammatory environment that contributes 
to allergic disease.   
The pro-inflammatory effects of PGD2 are mediated by both receptors via multiple 
signaling pathways whose activity is dependent on local receptor expression.  DP receptors are 
predominantly expressed on bronchial epithelium indicating that receptor activation mediates 
production of cytokines and lipid mediators that recruit DP receptor expressing cells such as: 
platelets, fibroblasts, DCs, T cells, basophils, eosinophils and mast cells [191].  Currently there 
are several experimental models that support and demonstrate DP receptor mediated airway 
inflammation and hyper-reactivity.  DP antagonists promote anti-inflammatory properties in 
experimental models that include the inhibition of antigen-induced conjunctivial micro vascular 
permeability in guinea pigs [192] and attenuated ovalbumin (OVA)-induced hyper-reactivity in 
mice [193].  The pro-inflammatory effect of DP signaling is further exemplified by the 
observation that mice deficient in the DP receptor have diminished airway hyper-sensitivity 
[194].  Therefore, DP receptor signaling is key in mediating the effects of mast cells released 
PGD2 on the airway epithelium inducing the release of specific cytokines and chemokines, such 
as IL-8 and GM-CSF, creating airway inflammation, obstruction and hyper-reactivity [194].   
PGD2 released by mast cells also mediates the activation, chemotaxis and infiltration of 
inflammatory cells that express the CRTH2 receptor.  This high affinity PGD2 receptor is 
expressed in type 2 polarized lymphocytes [195], basophils, eosinophils [196] and monocytes 
[197].  Signaling via CRTH2 is responsible for the activation and recruitment of Th2 cells, 
eosinophils, basophils and monocytes, initiating and driving eosinophilic and inflammatory cell 
infiltration [149, 197].  The chemotactic response to PGD2 by eosinophils, basophils and Th2 
cells is mediated by CRTH2.  This is substantiated by in vitro and in vivo studies that confirm 
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the chemotaxis of these cell types is in response to PGD2 signaling through the CRTH2 receptor 
not DP.  Specifically the, antagonism of CRTH2 receptor exhibited greatly decreased 
eosinophilic infiltration post antigen exposure in ramatroban-treated animals [198-199].  This 
was further validated by studies of a PDG2 double knockout model by Gervais et al.[200].  
Treatment with a CRTH2 agonist stimulated chemokine release and eosinophil degranulation, 
where as treatment with the DP agonist BW245C did not elicit these effects.  In this same study 
CRTH2 activation also lead to eosinophil shape changes, chemotaxis, enhancement of 
chemotactic responsiveness to other chemoattractants and degranulation, where as stimulation 
through DP activation induced eosinophil apoptosis.  Blocking DP activation using a selective 
antagonist BW A868C significantly enhances CRTH2-mediated activation indicated by 
increased CD11b expression post PGD2 stimulation [149-150].  Therefore, PGD2 activation and 
recruitment of eosinophils is controlled by a dual receptor system that requires collaboration 
between the two high affinity receptors, DP and CRTH2. 
PGD2 can act not only as a pro-inflammatory mediator during allergic inflammation, but 
also has the ability to act as an inhibitor of inflammation in specific contexts via DP receptor 
signaling.  The DP receptor is expressed by DCs that are responsible for initiating adaptive 
immune response when they come into contact with possible antigens.  Studies done by Hammad 
et al. [201] using a FITC-OVA mouse model of inflammation to observe dendritic cell activation 
and migration.  They show that the intratracheal instillation of FITC-OVA together with PGD2 
inhibits the migration of FITC+ lung DC to draining LNs [201].  Decreased DC migration 
decreases antigen specific T cell activation, proliferation and the production of antigen specific 
cytokines.  Under steady state conditions, macrophages might secrete PGD2 to suppress DC and 
T cell activation [202]. During inflammation, PGE2 and LTC4 are produced and induce 
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differentiation and maturation of tissue-resident DCs [167, 203]. Under these conditions, the 
anti-inflammatory effects of PGD2 are overridden by the pro-inflammatory effects of PGE2, 
LTC4, and pro-inflammatory cytokines. Also, at the resolution of inflammation, COX-2 enzyme 
mainly generates PGD2, rather than PGE2 [204]. The release of PGD2 might suppress DC 
migration to prevent further immune stimulation, thus contributing to the resolution of 
inflammation.  
The biological activity of PGD2 signaling is not restricted to the inflammatory effects of 
asthma alone, but is pertinent in the progression from chronic unresolved inflammation into 
permanent remodeling of the airway.  When airway inflammation is not adequately treated, it can 
result in permanent structural changes in the airways. such as increased airway wall thickness 
that involves both smooth muscle and collagen tissue and increased mucous production due to 
proliferation of airway epithelial goblet cells resulting in mucus hypersecretion.  Antigen 
induced expression of the high affinity DP receptor has been observed in both mouse bronchiole 
epithelial cells and human nasal epithelial goblet cells.  DP receptor expression combined with 
the ability of DP signaling to induce mucus secretion by colonic goblet cells insinuates the 
possibility that DP receptors may provoke mucus secretion in response to PGD2 in asthma and 
allergic rhinitis. 
PGs and Airway Remodeling 
PGs play an important role in maintaining airway homeostasis, by inhibiting remodeling 
processes.  This is best exemplified under the normal condition of the airway.  Under normal 
circumstances, the epithelium releases mediators, specifically PGE2, that restrict mesenchymal 
cell proliferation and activation [205].  Upon injury to the epithelium PGE2 production is 
diminished resulting in the induction of repair responses that promote remodeling.  
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Subsequently, the various mediators and growth factors that support the proliferation and 
survival of mesenchymal cells are released.  Specifically, fibroblast growth factor (FGF), insulin 
growth factor (IGF), platelet-derived growth factor (PDGF), endothelin-1 (ET-1) and TGF-β 
[206].  These factors induce inflammation and activation of cells involved in the repair response, 
specifically fibroblasts.  Therefore, PGE2 suppresses remodeling as demonstrated by the 
maintenance of homeostasis when it is present in the airway under normal conditions. 
Fibroblasts are the critical cells type involved in normal wound healing and whose 
apoptosis is required to prevent excessive matrix deposition or scarring.  They also produce 
numerous mediators that induce proliferation and activation of remodeling processes.  A critical 
feature of fibrotic lung disease is increased transition of fibroblasts into myofibroblasts or 
fibroblast like cells expressing α-SMA [207].  Furthermore, in areas of active fibrosis there are 
increased numbers of myofibroblasts that are associated with promoting fibrotic processes [50, 
208].  Myofibroblasts are the predominant source of increased collagen gene expression and 
production as demonstrated by the correlation between decreased lung compliance and their 
presence [209].  Not only do myofibroblasts alter tissue contractility and increase ECM 
synthesis, they also secrete mediators of fibrogenesis.  Myofibroblasts secrete two specific 
substances: monocyte chemotractant protein-1 (MCP-1) and TGF-β1 that induce inflammatory 
and fibrogenic processes [210-211].  These characteristics of myofibroblasts establish this cells 
type as a key catalytic factor in fibrosis [212].  PGE2 is a potent mediator of fibroblast activity, 
inhibiting their proliferation [213-214], survival [215], differentiation [216], growth factor 
expression [217], migration [218] and collagen synthesis [219-220].  By augmenting 
fibroblast/myofibroblast activity, PGE2 can regulate the fibrotic processes involved in the 
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development of disease and could be a relevant factor involved in avoiding pathological 
processes.   
Regulation of fibroblast proliferation involves two sides: an inducer of proliferation and a 
suppressor of proliferation, that act in opposition to maintain homeostasis.   Induction of 
proliferation occurs during injury and inflammation due to both decreased suppression and 
increased pro-proliferative signals.  For example, during inflammation AMs play a key role in 
initiating fibroblast proliferation by secreting fibronectin and macrophage-derived growth factor 
(AMDGF) [213]. In situations of injury and inflammation numerous secreted mediators such as 
TGF-β, FGF and IGF-1 increase due to infiltrating inflammatory cells or injured epithelium.  At 
the conclusion of inflammation or when repair has occurred suppression of profibrogenic 
mediators returns and the processes of repair cease.  Recently, it has been suggested that alveolar 
epithelial cells (AECs) are the primary producers of suppressive signals and that PGE2 is the key 
mediator.  This is supported by early studies by Bitterman et al. [213] that determined that PGE2 
inhibits fibroblast proliferative response to fibronectin and AMDGF in a dose dependent manner.  
This demonstrated for the first time that PGE2 is an inhibitor of fibroblast proliferation.  Further 
studies determined that PGE2 is a relevant endogenous anti-proliferative mediator of fibroblasts 
because mice deficient in PGE2 demonstrate exaggerated fibroblast proliferation [221-222].  
Therefore, it was determined that AECs suppressed fibroblast proliferation by secreting PGE2 
and loss of AEC suppression results in repair.  The importance of PGE2 suppression of 
profibrogenic processes is key in avoiding fibroproliferative diseases and may be relevant in 
understanding the processes involved.      
Fibroblast differentiation into myofibroblasts is necessary for wound healing or 
remodeling to occur [223].  The main function of myofibroblasts is to form adhesions between 
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the wound edge and the ECM.  These adhesions allow them to pull the ECM when they contract, 
reducing the wound size by pulling the wound edges together.  Fibroblasts lay down collagen to 
reinforce the wound as myofibroblasts contract to allow for complete repair [40].  α-SMA 
provides the contractile ability to fibrocytes and is the main identifying marker of myofibroblasts 
[51, 208-209].  At least three local events are needed to generate α-SMA-positive differentiated 
myofibroblasts: 1) accumulation of biologically active TGF-ß1, 2) the presence of specialized 
ECM proteins like the ED-A splice variant of fibronectin, and 3) high extracellular stress, arising 
from the mechanical properties of the ECM and cell remodeling activity [40, 208].  IL-1β and 
IFN-γ have been shown to down regulate the expression of α-SMA mRNA and protein as well as 
decrease fibroblast proliferation and collagen synthesis [209, 224-225] .  More importantly, 
PGE2 was shown by Kolodsick et al. [216] to inhibit TGF-β1 induced α-SMA expression 
through the EP2 receptor.  PGE2 is able to limit synthesis of matrix collagen and prevent 
fibroblast transition, two prominent components of remodeling [216].  It also induces fibroblast 
apoptosis, preventing excessive matrix deposition or remodeling [215].  Huang et al. [215] 
demonstrated that PGE2 signaling via EP2 or EP4 induced fibroblast apoptosis.  Apoptosis was 
modulated by different survival pathways such as activation of both caspase 8 and 9 [215], Fas 
ligand [215] and enhanced phosphatase and tensin homolog (PTEN) activity [218, 226]. 
Signaling through EP2 also prevents fibroblast chemotaxis and migration as well as its 
production of collagen [218-219].  Therefore, PGE2 is a key regulator of fibroblast activity [227]. 
PGE2 not only regulates the fibroproliferative aspects of remodeling, it also suppresses 
the inflammatory component.  Inflammation is a key component in remodeling, where the 
inflammatory response provides the cells and mediators responsible for repair.  PGE2 opposes 
leukocyte accumulation through numerous different mechanisms.  It inhibits myelopoiesis, 
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diminishing the available cells who could participate.  It also inhibits the recruitment and 
chemotaxis of inflammatory cells deterring their accumulation.  The activation of cells and 
secretion of inflammatory mediators that are involved in remodeling is also effected by PGE2.  
PGE2 negates the production of a variety of inflammatory mediators, including reactive oxygen 
species, IL-8, TNF-α, FGF, ET-1 and LTs.  It also up-regulates the expression of the suppressive 
mediator IL-10, which also induces anti-inflammatory aspects.  This demonstrates that PGE2 is 
paramount in suppressing aspects of the inflammatory response that could lead to remodeling. 
Leukotrienes (LTs) Synthesis 
The synthesis of LTs is initiated by 5-lipoxygenas (5-LO) with the assistance of 5-
lipoxygenase activating protein (FLAP) [228] as shown in Figure 7.  FLAP serves as a 
membrane anchor for 5-LO and acts as an amine bind protein to enhance its ability to interact 
with its substrate [229].  More importantly it is necessary for the activation of 5-LO’s enzymatic 
activity and therefore essential for LT synthesis [230-231].  FLAP and 5-LO oxygenate 
arachidonic acid to produce leukotriene A4 (LTA4), the unstable precursor of all LTs [232].  
LTA4 is either conjugated with reduced glutathione by leukotriene C4 synthase making 
leukotriene C4 (LTC4) or hydrolyzed by leukotriene A4 hydrolase to form leukotriene B4 (LTB4) 
[233].  Both LTB4 and LTC4 are then transported out of the source cell by specific transporter 
proteins [233].  Exported LTC4 undergoes sequential peptide cleavage events to produce 
leukotriene D4 (LTD4) and finally leukotriene E4 (LTE4).  LTC4, LTD4 and LTE4 are known as 
the cysteinyl leukotrienes (cysLTs).   
Leukocytes are the primary producers of LTs because they are the only cells that express 
sufficient 5-LO and FLAP to synthesize appreciable amounts [138].  Incidentally, non leukocyte 
cells that express distal LTA4 metabolizing enzymes can take up leukocyte derived LTA4 and 
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produce LTs by a process called transcellular biosynthesis [234].  The primary example of this 
process is the interaction between neutrophils and endothelial cells.  In this case, neutrophils 
produce and release LTA4 that endothelial cells take up and metabolize into LTC4 using their 
LTC4 synthase, demonstrating another source of LTs.  
LT Receptors 
LTs exert their biological activity by binding to specific heptahelical receptors of the 
rhodopsin class that are expressed on the outer plasma membrane of structural and inflammatory 
cells [235-236].  These receptors signal through G proteins in the cytoplasm that induce 
increases in intracellular calcium and reductions in intracellular cAMP.  Changes in intracellular 
cAMP and Ca2+ activates different downstream kinase cascades that can then alter cellular 
activity [233].  Resulting changes in cellular activity is dependent upon the LT and cell types 
involved as shown in figure 10.   
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Figure 10 LT Activity 
Leukotrienes synthesis, secretion, receptor binding and biological action.   LTA4 and LTB4 can potentially be formed on either 
side of the nuclear envelope by nuclear- or cytosolic-localized pools of 5-LO and LTA4 hydrolase in macrophages and mast cells.   
The LTB4 transporter can facilitate transfer of LTB4 out of the cell, where it can act on neutrophils through the BLT1 receptor, 
inducing chemotaxis and recruitment.  LTA4 can also be converted to LTC4 by LTC4 synthase, a FLAP-like protein found in the 
nuclear envelope. The multidrug resistance-associated protein-1 (MRP1) can transport LTC4 out of the cell, where it is 
metabolized by extracellular-localized g-glutamyl transpeptidase (GGT) or g-glutamyl leukotrienase (GGLT) to LTD4.  LTD4 
can bind to the cysLT1 receptor on both endothelial cells and airway smooth muscle cells or be further metabolized to make 
LTE4. 
LT receptors were originally divided into two classes known as B leukotriene receptors 
(BLT) and CysLT receptors based on ligand preference.  There are two BLT receptors, BLT1 and 
BLT2 that preferentially bind LTB4 (Figure 8).  BLT1 is the high affinity receptor for LTB4 that 
mediates almost all of its signaling, whereas the role of the lower affinity BLT2 receptor is not 
well known.  There are two cysLT receptors: type 1 and type 2 cysteinyl leukotriene receptor 
(cysLT1 and cysLT2).  CysLT1 ,mediates sustained bronchoconstriction, mucus secretion and 
edema in the airways [237].  CysLT2 is responsible for mediating inflammation, vascular 
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permeability and tissue fibrosis [237].  Combined these receptors induce the different biological 
effects of LTA4 and the cysLTs. 
LTs and Airway Inflammation 
LTB4 
LTB4 is a potent lipid inflammatory mediator involved in regulating aspects of allergic 
airway inflammation and the pathogenesis of asthma.  LTB4 is a prominent chemoattractant for 
PMNs [238], but it also influences the chemotaxis of monocytes, macrophages and eosinophils 
[239-240].  In addition to its potency as a chemoattractant, LTB4 serves as an activator of PMNs 
through BLT1 receptor signaling [241].  PMN BLT1 receptor signaling promotes two functions 
that are key components of PMN inflammatory responses.  BLT1 receptor ligation encourages 
cPLA2 cleavage of membrane phospholipids releasing arachidonic acid that is converted into 
LTs [242].  Also, LTB4 signaling induces PMN degranulation resulting in release of 
inflammatory mediators that can dictate the local inflammatory response [243].  Therefore, LTB4 
is an important mediator of the early phases of inflammation that include the recruitment and 
activation of inflammatory cells that create the inflammatory environment. 
MCs play a central role in inflammatory and immediate allergic reactions.  Studies by 
Weller et al. [244] revealed that LTB4 acts as an autocrine mediator of MCs.  In this study, MC 
progenitor cells derived from either BALB/C bone marrow or heparin treated human umbilical 
cord blood were shown to express the BLT1 receptor, indicating LTB4 involvement in early mast 
cell activation.  Result of an in vitro chemotaxis assay demonstrated that LTB4 released by 
activated MC is an effective chemotractant for MC progenitors.  In addition, in vivo studies 
demonstrated the accumulation of adoptively transferred fluorescent labeled c-Kit+ MC 
progenitor to the site of subcutaneous injection of LTB4.  Weller et al.’s results indicate that 
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LTB4 is a potent chemoattractant for MC progenitor cells, but not for mature MCs.  The response 
to LTB4 is temporal, dissipating with the maturing of MCs which corresponds with the decrease 
in BLT1 receptor mRNA expression and chemotaxis by mature MCs.  This temporal shift of 
LTB4 sensitivity allows for immature MCs to be recruited to sites of inflammation and prevents 
concentration of mature MCs to the site of focal allergen stimulus, depleting mature MCs from 
the periphery.     
It was more recently determined that LTB4 signaling through BLT1 is an important 
mediator of T cell recruitment and activation in allergic inflammation [245].  Miyahara et al. 
[246]  found that during the course of naive CD4+ T cell differentiation, the LTB4 receptor BLT1 
is expressed and functional on Th1 and Th2 effector cells. In addition, antigen-specific effector 
CD4+ T cells generated in vivo up-regulated BLT1 when they migrated out of the lymphoid 
compartment and were recruited into tissue. BLT1 mediated LTB4-induced Th1 and Th2 cell 
chemotaxis and firm adhesion to endothelial cells under flow. Furthermore, BLT1 mediated early 
CD4+ and CD8+ T cell recruitment into the airway in a model of allergic pulmonary 
inflammation.  This indicates that the LTB4-BLT1 pathway is involved in linking early immune 
system activation and early effector T cell recruitment.   
In conjunction with LTB4 and BLT1 ability to recruit effector T cells, it can also play an 
important role in initiating and developing a Th2-type immune response that is focal in airway 
hyper responsiveness (AHR) [245, 247].  In the absence of BLT1 expression, development of 
AHR was attenuated, but not completely abrogated in mice in an OVA-induced bronchial asthma 
model [246].   BLT1
-/- mice developed significantly lower airway responsiveness to inhaled 
methacholine, lower goblet cell hyperplasia, decreased IgE expression and decreased Th2 
cytokine expression, specifically IL-13 production in vivo and in vitro as well as IL-5 in vivo 
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[246].  It was also determined that the development of Th2 cells was also impaired in the absence 
of BLT1 [247].  When BLT1
-/- mice received allergen sensitized BLT1
+/+ T cells through adoptive 
transfer the development of AHR was fully restored as well as Th2 cytokine production and Th2 
cell development [246].  Thus LTB4 and BLT1 interaction plays an important role in initiating 
and developing Th2 type immune response and the full development of AHR. 
Cysteinyl Leukotrienes (cysLTs) 
CysLTs are recognized as potent inflammatory mediators that initiate and propagate a 
diverse array of biological responses in the airway.  They are best known for their contractile 
effects on the smooth muscle and endothelium [248-249].  For example, in the airway cysLTs 
bind to cysLT1 receptors expressed on airway smooth muscle resulting in bronchoconstriction 
[237].  CysLT regulation of muscle tone is intimately associated with the regulation of vascular 
permeability and vasoconstriction [249].  Changes in vascular permeability are key in allowing 
for inflammatory cell extravasation and migration to different sites of inflammation.  Changes in 
permeability also control plasma protein leakage which can develop into edema.  Therefore, 
cysLTs signaling through cysLT1 plays an important role in the muscle tone of the airway and 
vasculature.   
CysLTs serve as a chemotactic mediator and activation stimulus for effector leukocytes 
such as macrophages, monocytes and eosinophils.  CysLTs have been shown to influence both 
progenitor and differentiated immune cells through both receptors.  It was observed that the 
cysLT1 receptor, but not cysLT2 receptor, are expressed on CD34
+ peripheral blood derived 
progenitor cells [250].  In vitro treatment of these cells with cysLTs induced transendothelial 
migration, which was inhibited by pretreatment with Monteleukast (cysLT1 receptor antagonist) 
[250].  Monteleukast inhibition was not present in mature peripheral blood leukocytes, indicating 
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that the cysLT1 receptor is no longer the primary means of leukocyte signaling, with the cysLT2 
receptor taking its place.  CysLT2 receptor expression occurs during development and may be 
important in differentiating progenitor cell and mature cell cysLT signaling.  CysLT signaling is 
a stimulus for activation of peripheral leukocytes and is dependent upon the expression of cysLT 
receptors which is regulated by cytokines.  For example, treatment of peripheral blood 
monocytes or macrophages with IL-4 or IL-13 induces increased cysLT1 receptor expression 
[251].  Enhanced receptor expression results in amplified cysLT chemotaxis.        
CysLTs pro-inflammatory characteristics have long been associated with the activity of 
eosinophils in allergic inflammation. The migration of eosinophils into the airway involves 
several steps; including eosinophilopoesis and release from the bone marrow, up regulation of 
adhesion molecules on eosinophils as well as on the vascular endothelium and the increase in 
chemoattractant molecules released into the airways.  CysLTs have been associated with each 
aspect of increased airway eosinophilia.  The increase in the number of eosinophils through 
eosinophilopoesis is regulated by cysLT1 receptor signaling in combination with IL-13 and 
eotaxin [252].  In addition, the proliferation of eosinophils that occurs during allergic reactions is 
controlled by LTD4 in combination with the growth factors, granulocyte-macrophage colony-
stimulating factor (GM-CSF) and IL-5 [253].  Therefore, cysLT signaling increases the number 
of eosinophils present in the airway.  Eosinophil recruitment is facilitated by cysLT regulation of 
adhesion molecules on both the endothelium and on eosinophils.   P-selectin, an adhesion 
molecule that is expressed on activated endothelial cells, function to recruit eosinophils and other 
leukocytes to the site of inflammation.  CysLTs LTC4 and LTD4 induce surface expression of 
endothelial P-selectin [254], and further assist in the accumulation of eosinophils.  To increase 
eosinophil migration, cysLTs also up regulate β2-integrin expression on eosinophils, stimulate 
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vascular endothelial cells to produce PAF and increase adhesion of leukocytes [255-256].  The 
Combined efforts of cysLT signaling are meant to increase eosinophil chemotaxis to sites of 
inflammation.  Once they arrive, cysLT signaling is able to induce survival of eosinophils in 
order to maintain the inflammatory reaction [257].  Therefore, cysLT activity is prominently 
involved in controlling eosinophil differentiation, proliferation, chemotaxis, migration and 
survival.  
CysLTs influence the adaptive immune response through their ability to mediate the 
maturation and migration of DCs [203].  In vivo studies using multidrug-resistance associated 
protein-1 deficient mice, which have impaired responses to arachidonic acid stimulated 
inflammation because this protein is the major transporter for LTC4, exhibited significantly 
suppressed DC migration compared with wild type controls [203].  Injection of LTC4 or LTD4 
reversed the suppression of DC migration [203].  DCs produce endogenous LTC4 when initially 
exposed to antigen which serves as a critical determinant for homing to regional lymph nodes, 
indicating why disruption of LTC4 synthesis suppressed DC migration.  
DC migration is an important step in the activation of an adaptive immune response, but 
not the only important function of DCs in regulating the adaptive response.  DCs also play an 
important part in controlling the type of T cell response based on the type of antigen and 
chemical mediators present.  CysLTs play an important part in directing DC immunomodulatory 
functions.  In order to determine the effect of cysLTs on airway inflammation Machida et al. 
[258] used murine bone marrow derived DCs pulsed with mite allergens, Dermatophagoides 
farinea (Der-f) and then analyzed for production of in vitro cytokines with or without exogenous 
cysLT treatment.  Preliminary findings demonstrated that DCs produce cysLTs in response to 
aeroallergens and express the cysLT1 receptor.  Analysis of cytokine production showed Der f 
53 
 
induced increased production of IL-10 and IL-12 compared to controls.  Der f and cysLT pulsed 
DCs produced significantly higher levels of IL-10 compared to Der f alone but with similar IL-
12 levels.  Treatment of DC with Der f and the cysLT1 antagonist LTRA demonstrated increased 
levels of IL-12 and decreased levels of IL-10.  This is important because higher levels of IL-12 
and low levels of IL-10 are associated with the development of a Th1 response [259-262], while 
higher levels of IL-10 and lower levels of IL-12 are associated with a Th2 response [263].  
Therefore, these results demonstrate that cysLTs induce the production of a cytokine profile 
promoting a Th2 response, with higher levels of IL-10 and lower levels of IL-12.  The pulsed 
DCs were then subsequently instilled into the airways of naïve mice that were then exposed to 
Der f to determine in vitro effects of cysLTs on DCs.  They analyzed the pathology and BAL 
cytokine profiles of the mice to find that instillation with Der f DCs induced allergic airway 
inflammation characterized by increased eosinophilia and IL-5 production.  The addition of the 
cysLT, LTD4, leads to an even greater number of eosinophils in the airway and increased 
production of IL-5.  In contrast, mice instilled with DCs pulsed with Der f and LRTA showed 
reduced eosinophilia and IL-5 production in the airway, but demonstrated increased IFN-γ.  
Therefore, in vivo and in vitro studies demonstrated that cysLT treatment influences airway DCs 
to initiate a Th2 response, directly affecting the adaptive immune response.         
CysLTs influence over the adaptive immune response not only involves the regulation of 
DC immunomodulatory functions, but also involves regulating the initiation and amplification of 
Th2 cell dependent inflammatory responses.  Th2 cell dominant inflammatory responses are a 
prominent component of asthma and the development of AHR [264-265].  LTB4 and BLT1 
signaling have been established as key factors in the regulation AHR mechanisms [247, 266].  
These mediators are known as inducers of AHR by their ability to recruit and activate IL-13 
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producing effector/memory T cells, but they also work in concert with cysLTs [267].  Kim et al. 
[268] used mice with a targeted disruption of LTC4 synthase to determine the role of cysLTs in 
the development of Th2 cell dependent inflammation in the airways.  They found that LTC4S
null 
mice diminished manifestations of Th2 cell dependent pulmonary inflammation.  More 
specifically, accumulation of eosinophils and lymphocytes, goblet cell hyperplasia and mucus 
production, IL-4, IL-5 and IL-13 transcription and secretion and serum IgE and IgG1 were all 
diminished in LTC4S
null mice.  This demonstrates that cysLTs are key in regulating the adaptive 
immune response in their ability to initiate or amplify Th2 dependent inflammation.   
Leukotrienes and Airway Remodeling 
The key features of airway remodeling include: the accumulation and activation of 
inflammatory cells, a Th2 cell immune response phenotype, mesenchymal cell hyperplasia and 
increased matrix protein deposition.  Looking at theses hallmarks of airway remodeling it is 
apparent that LTs play an important role in the process.  LTs increase the number of 
inflammatory cells present in the airway through various modes of action.  LTB4, as stated 
above, is known to be a potent chemoattractant for neutrophils, eosinophils, macrophages and 
lymphocytes (effector T cells).  CysLTs provide increased means of inflammatory cell 
extravasation by up regulating endothelial cell adhesion molecule expression.  Additionally, LT 
signaling can inhibit apoptosis of recruited cells, such as neutrophils and eosinophils.  When the 
activity of LTs is blocked either through inhibition of synthesis or receptor antagonism 
inflammatory cell accumulation is attenuated.  Therefore it is apparent that LTs play an 
important role in the first part of airway remodeling. 
Th2 cell dominated inflammatory responses are associated with the development of AHR 
and remodeling.  cysLTs and LTB4 have been shown to regulate the initiation and amplification 
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of a Th2 dominant immune response.   LTB4 BLT1 interaction is mandatory for the recruitment 
of T cells and the initiation and development of a Th2-type immune response [246] as 
exemplified by reduced AHR associated with decreased IL-5, IL-4 and IL-13 production in 
BLT1null mice.  Specifically, LTB4 – BLT1 roles include: influencing DC migration to lymph 
nodes for T cell activation [246], attracting and activating lymphocytes (CD4 and CD8 T cells) 
[266], recruiting and activating IL-13 producing T cells [269] and stimulating T cell production 
of IL-4 and IL-5 [247].   Similarly, cysLTs regulate the initiation and amplification of Th2 cell-
dependent inflammation.  They influence airway DCs to initiate a Th2 response [258] and induce 
the production of Th2 cytokines IL-4 and IL-5 [268].  Combined, the cysLTs and LTB4 are 
prominent mediators involved in the initiation, activation and development of Th2 immune 
responses and are therefore relevant to the process of airway remodeling.    
Mesenchymal cell hyperplasia results in airway smooth muscle cell and fibroblast 
proliferation.  Studies have implicated that LTs augment both cell types and are key in inducing 
proliferation.  Studies by Vannella et al [270] demonstrated that cysLTs regulate fibrocyte 
function via autocrine and paracrine signaling.  They found that LTD4 induces fibrocyte 
proliferation to greater extent than LTC4 [270].  The mitogenic properties of LTD4 are solely 
mediated by the cysLT1 receptor as demonstrated by augmented fibrocyte proliferative response 
to LTD4 when treated with cytLT1 antagonists [271].  LTD4 along with LTB4 has also been 
shown to augment airway smooth muscle cell (ASM) proliferation when combined with 
epidermal growth factor (EGF) or IGF [272].  However, LT signaling combined with growth 
factors has no implication in altering collagen or ECM proteins. 
CysLTs may modulate extracellular matrix remodeling during pulmonary inflammation.  
Primarily, cysLTs are able to influence fibroblast activity, specifically they induce the secretion 
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of FGF which can induce increased collagen synthesis.  Studies have implicated that collagen 
synthesis can be induced by LTC4, and LTE4 as demonstrated in rat lung fibroblasts.  The role of 
cysLTs in collagen deposition is further verified by the dramatic reduction of airway collagen 
deposition by Monteleukast treatment in a chronic mouse asthma model, indicating a potent anti 
fibrotic pathway through cysLT1.  
Eicosanoids & Fibrosis 
LTs and PGs work in opposition of one another to create a balance resulting in 
homeostasis.  The overproduction of profibrotic and proinflammatory LTs and diminished PGE2 
is associated with the development of fibrotic disorders.  Evidence supporting the pivotal role for 
eicosanoids in fibrotic lung disease derives from observations that human and animal models of 
pulmonary fibrosis exhibit a synthetic imbalance favoring profibrotic LTs.  The amount of LTB4 
in bronchoalveolar lavage fluid (BAL) isolated from patients with IPF was greater than the 
amounts isolated from normal volunteer’s samples [273-274].  Similarly, lung homogenates from 
IPF patients contained 15 fold greater LTB4 and 5 fold higher cysLTs that did normal controls 
[275].  Interestingly, the increased levels of LTs correlated directly with the histological severity 
of fibrosis, indicating a possible link between LTs and the progression of fibrosis.  The source of 
LT overproduction are the AMs and is believed to be caused by constitutive activation of the 5-
LO enzyme.  The observation of increased LT levels in the lung gathered from IPF patients 
correlated with the results of bleomycin induced fibrosis in both mice and hamsters, indicating 
the importance of LT expression in fibrotic disease. 
The cause of increased LT synthesis in fibrotic lungs has not been identified, but a 
number of possible mediators are relevant candidates due to their elevated expression in the 
fibrotic lung and their ability to stimulate constitutive 5-LO activity.  Candidates include 
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cytokines, such as IL-8 [276], IL-4 [277] and IL-5 [278], immune complexes [279], MCP-1 
[280], endothelin-1 [281] and TGF-β [282-283].  Further studies are necessary to determine the 
stimulus and mechanism responsible for increased LT levels. 
The underproduction of PGE2 diminishes any suppression of profibrotic signaling.  This 
seems to be the case as determined from IPF patients and different animal models of fibrosis.  
BAL fluid from patients with IPF contains lower levels of PGE2 than BAL from controls.  
Fibroblasts isolate from IPF patient lung tissue demonstrate a reduced ability for PGE2 synthesis.  
The synthetic capacity by IPF fibroblasts is impaired under normal basal condition as well as in 
response to stimuli, such as LPS, IL-1, TNF-α and TGF-β.  Impaired COX-2 mRNA and protein 
is responsible for the diminished synthetic activity.  COX-2 is important in different 
inflammatory and induced settings; loss or diminished activity of this enzyme leaves cells unable 
to respond to their environment.  Since PGE2 serves as an important counter signal to fibroblast 
proliferation and activation, the loss of its activity is a relevant and important component in 
fibrosis. 
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CHAPTER 4    
Effects of Reovirus Exposure on Airway 
Reponses in an Experimental Model of Lower 
Respiratory Tract Infection (LRTI) 
Rational 
Viral LRTI early in life has been reported as a potent initiating factor for the subsequent 
development of childhood asthma [1, 284-285].  Furthermore, LRTIs, such as viral bronchiolitis, 
are the leading cause of child and infant hospitalization, with an estimated 120,000 hospital 
admissions annually [286].  RSV is the predominant cause of severe bronchiolitis and pneumonia 
in infants worldwide [287]. In addition, there is growing evidence that early RSV infection is an 
important risk factor for the development of recurrent wheezing during the first decade of life 
[1].  Other common early life viral pathogens such as rhinovirus, influenza, parainfluenza (PIV), 
adenovirus, human metapneumovirus (hMPV), and human boca virus (hBoV) are known 
etiological agent of viral bronchiolitis [288-291].  Similarly, reoviruses are commonly found in 
the airways of exposed infants early in life [3-5] and are associated with pulmonary infections 
and the common cold [6].  The increased rate of reovirus infection during early childhood 
combined with the lack of information regarding the mechanisms behind its pathogenesis 
suggests that reovirus could be relevant in the development of childhood asthma.      
Previous studies in animal models have shown that RSV infection results in dysregulated 
neuroimmune interactions and altered synthesis/release of pro-inflammatory neuropeptides 
generating amplified airway reactivity and neurogenic-mediated inflammation [284].  The 
essential and pivotal result of RSV infection is increased expression of Nerve Growth Factor 
(NGF) and its high affinity receptor tyrosine kinase A (TrKa) in the lungs [292].  NGF is the 
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central regulatory factor controlling development, responsiveness and the level of 
neurotransmitter expression and transcription [293-294].  NGF increased expression and 
signaling results in augmented synthesis and release of the proinflammatory neurotransmitter 
substance P(SP) by nociceptive fibers of the lower respiratory tract [295].  Concomitantly, 
augmented NGF induces the over expression of SP’s high-affinity receptor, neurokinin 1 (NK-1), 
by inflammatory cells and on the airway epithelium and vascular endothelium, resulting in 
exaggerated neurogenic inflammation [295].  Therefore, RSV-induced release of NGF primes 
different cellular effectors of the immune system (e.g., lymphocytes, monocytes, MCs), 
rendering them susceptible to the modulatory influence of the increased abundance of SP.  The 
alterations to the airway sensory innervations induced by RSV infection early in life could 
predispose infants and children to the development of asthma. 
The results of different studies indicate that the development of neurogenic inflammation 
is exceedingly dependent upon viral LRTI occurring early in life.  Although to a lesser extent 
than RSV, reovirus exposure has been shown to be relevant within a critical time frame for the 
developing lung. Very little is known about the neurogenic-mediated airway responses following 
exposure to reovirus and their potential impact on the development of asthma later in life.  
Therefore, we wished to investigate the neurogenic inflammatory response to reovirus infection 
in an animal model of lung infection.    
In addition, reovirus respiratory infection has been previously reported to generate 
increased collagen deposition and fibroblast proliferation.  Specifically, Bellum et al. [38] 
reported that CBA/J mice infected with reovirus T1/L demonstrate a pathology of increased 
collagen deposition and fibroblast proliferation, making it an ideal animal model for BOOP.  
However, the processes and underlying mechanisms of fibrosis have not been clearly elucidated.  
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Cav-1 and the eicosanoids, PGE2 and cysLTs, have been reported as principal mediators of 
fibrotic disease and may be important in the pathogenesis of reovirus induced fibrosis.  
Therefore, we investigated the effect of reovirus on airway remodeling and the relevance of cav-
1 and the eicosanoids reovirus pathogenesis.      
Specific Aim 1:  To investigate the effects of reovirus exposure on 
physiological airway responses and whether these responses were 
associated with neurogenic inflammation. 
Specific Aim 2: To investigate the effects of reovirus exposure on 
expression neurotrophins and their receptors.    
Specific Aim 3: To investigate the effects of reovirus exposure on 
airway remodeling. 
Material and Methods 
Animals 
Adult rats (12 week-old) of both sexes and weanling rats (2 week-old) born to pathogen-
free timed pregnant dams of Fischer 344 (F-344) strain were obtained from Harlan Sprague 
Dawley Inc. (Indianapolis, IN). Due to the profound effects of respiratory infections on 
neurosensory airway regulation [296], the animals were kept in polycarbonate micro-isolator 
cages in a strictly controlled pathogen-free environment to prevent any microbial cross-
contamination. These cages were placed on racks that provided positive individual ventilation 
with class 100 air to each cage at the rate of approximately one cage change of air per minute 
(Maxi-Miser; Thoren Caging System, Hazleton, PA). We used separate rooms for housing 
reovirus-infected and pathogen-free rats, serviced by trained husbandry technicians. All 
manipulations, inoculation and cage maintenance, were conducted inside class 100 laminar flow 
hoods. Bedding, water and food were autoclaved prior to use and unpacked only under laminar 
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flow. Cages and water bottles were run through a tunnel washer after every use and disinfected 
with both chemical and heat. The West Virginia University Animal Care and Use Committee 
(WVU-ACUC) approved all experimental procedures followed in this study. 
Virus Preparation and Titration 
Reovirus was prepared according to a previously published method [297]. Briefly, 
reovirus serotype 1, strain Lang (T1L) stock, was originally obtained from Dr. Donald H. Rubin 
(Nashville, TN) and amplified in mouse L929 cells. Third-passage reovirus was purified by 
extraction with 1,1,2-trichloro-1,2,2-trifluoroethane followed by CsCl gradient centrifugation. 
The concentration of virions in the purified preparation was determined by measuring the optical 
density at 260nm according to the method of Smith et al. [297]. The infectious viral dose was 
determined by plaque assay. Before inoculation, the virus stock was diluted for a final 
concentration of 2.5x106 PFU/µl (High dose) and 7.5x102 PFU/µl (Low dose). Virus-free media 
was used as a negative control. 
Inoculation 
Adult rats were anesthetized with pentobarbital sodium (50 mg/kg i.p.). The trachea was 
carefully intubated with a 16-gauge cannula and 100 µl of a suspension containing reovirus at 
either high dose or low dose or virus-free media was injected over the airway mucosa using 1 ml 
syringe.  
Weanling rats were anesthetized with pentobarbital sodium (25 mg/kg i.p.). 40µl of 
suspension containing reovirus at either high dose, low dose or virus-free media was carefully 
pipetted into the back of the weanling’s throat and aspirated into the lungs. 
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Vascular Extravasation 
The extravasation of Evans Blue-labeled albumin from the tracheobronchial circulation 
was used as a marker of neurogenic-mediated inflammatory responses [298-299] following 
reovirus infection. Rats were anesthetized with pentobarbital sodium (adults: 50 mg/kg i.p.; 
weanlings: 25 mg/kg i.p.).  The tracer, Evans blue dye (30mg/kg given i.v. over 5 sec.) was 
injected into the left femoral artery.  Immediately after the injection of the tracer, virus infected 
and control rats were intravenously injected with 75 µg/kg of capsaicin (8-methyl-N-vanillyl-6-
nonenamide; Sigma-Aldrich, St. Louis MO) dissolved in a vehicle with a final concentration of 
0.75% ethanol, 0.375% Tween 80, and 0.85% NaCl in aqueous solution over 2 min through the 
right femoral artery.  The chemical was delivered in a volume of 1 ml/kg of body weight.  Five 
minutes after injection of the tracer, the chest was opened and a 22-gauge cannula was inserted 
into the ascending aorta through the left ventricle.  After incision of the left atrium, the 
circulation was perfused with 100 ml of PBS (adult rats) or 50 ml of PBS (weanling rats) over 2 
min using a syringe pump.  The extra pulmonary airways (from the first tracheal ring to the end 
of the main stem bronchi) and the left lung were dissected and prepared for Evans blue 
extraction. The connective tissue was carefully removed and the trachea was cut along the 
ventral side. The specimens were blotted dry, weighed and incubated in formamide for 18 hours 
at 50°C to allow the tracer to diffuse into the formamide. The extravasation of Evans blue-
labeled albumin from the tracheobronchial circulation was quantified by measuring the optical 
density of the formamide extracts at a wavelength of 620 nm. The quantity of Evans blue dye 
extravasated into the airway tissues, expressed in nanograms per milligram of wet-tissue weight, 
was interpolated from a standard curve of Evans blue concentrations (0.5–10 µg/ml). 
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Neurotrophin Immunoassay 
 NGF and BDNF protein expression in the lungs were measured with a commercial kit 
(Promega, Madison, WI) using the antibody-sandwich technique.  In brief, 100 mg of lung-tissue 
samples were homogenized in 5 volumes of lysis buffer that contained 20 mM Tris ·  HCl, 
150 mM NaCl, 1% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml 
aprotinin, 1 µg/ml leupeptin, and 0.5 mM sodium vanadate. The supernatants of homogenized 
tissue samples were incubated for 18 h at 4°C in 96-well plates coated with 100 µl of either anti-
NGF or anti-BDNF polyclonal antibodies (1.5 µg/ml in 100 mM carbonate coating buffer; pH 
9.7) to bind NGF or BDNF from the homogenates. After washing, a specific rat monoclonal 
antibody was applied (0.6 µg/ml in buffer, 100 µl/well) and incubated for 18 h at 4°C to bind the 
captured NGF or BDNF. The plates were again thoroughly washed, and horseradish peroxidase-
conjugated antibody to rat IgG was added to each well and incubated for 3 h at room temperature 
to detect the amount of specifically bound monoclonal antibody. After final washing to remove 
unbound antibody conjugate, the chromogenic substrate was added, and the color change 
generated by the reaction was read at a 450-nm wavelength. Test samples and NGF or BDNF 
standards (100 µl/well) were measured in duplicate. With this assay, NGF and BDNF can be 
quantified with a lower detection limit of 15.6 pg/ml and <2% cross reactivity with other 
neurotrophic factors.  
 
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
The presence of RNA in lung tissue was detected by RT-PCR in lung tissue specimens. 
The lungs were collected from the animals upon euthanasia with an i.p. dose of pentobarbital 
sodium followed by exsanguination. The tissue specimens were immediately flash frozen in 
liquid nitrogen and stored at -80°C. The frozen specimens were then placed in RLT disruption 
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buffer and homogenized using a conventional rotor-stator homogenizer (Brinkmann Instruments, 
Westbury, NY) for 45-60sec until each sample was uniformly homogenous. Total RNA was 
extracted from lung homogenates using RNEasy Midi-Kits (Qiagen GmbH, Hilden, Germany) 
according to the manufacturer’s specifications. RNA samples (1pg-2mg) were added to a 50µl 
master mix consisting of 400uM each of deoxynucleotide triphosphates (dNTPs), 10 units of 
RNAse inhibitor, 2µl of an enzyme mix containing Taq DNA Polymerase (one-step RT-PCR 
Promega, Madison, WI) and 50 pmol each of primers flanking the nucleotide sequence for NGF, 
BDNF, p75, TrKa, TrKb, and the housekeeping gene β-Actin. The same master mix without the 
RNA sample was used as a negative control. The primer pairs were designed on the basis of 
previously published protocols [300] and were used to differentiate cDNA-generated PCR 
products from genomic DNA contamination. The specific primer sequences (sense and 
antisense) are illustrated in table 1. Amplification was performed using a Gene-Amp PCR 
System 9600 thermal cycler (Perkin-Elmer, Waltham, MA). The process was started with an 
initial step of 50°/30 min then 95°/15 min followed by 25-35 cycles with a denaturing step 
followed by an annealing step, an extension step, and then one final extension step at 68-72° for 
10 min. All programs included a 4° hold step at the end. Amplified PCR products were size-
fractionated by electrophoresis through a 2% agarose gel and stained with ethidium bromide. The 
gels were then photographed using an imaging system (FOTO/Analyst Luminary Workstation, 
Fotodyne, Hartland, WI). The intensity of DNA bands were analyzed by computerized 
densitometry (TotalLab TL-101 Image Analysis Software) and expressed as the ratio of the 
densitometric score measured for each target normalized by the β-actin control. The primer 
sequence (sense and antisense) for all gene targets and their expected size is shown in Table 1. 
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Histopathology 
The right lung from each animal was fixed in 10% buffered formalin, embedded in 
paraffin, and cut in 3-mm-thick sections. Hematoxylin and Eosin (H&E) and Masons Trichrome 
staining was performed for histopathologic analysis. All slides were coded and interpreted by 
two independent pathologists who were blinded to whether the specimens were coming from an 
infected animal or a control. Histopathologic changes were graded as mild (5-10 inflammatory 
cells in 3 or more adjacent alveoli), moderate (10-20 inflammatory cells per alveolus), or severe 
(> 20 inflammatory cells per alveolus).  
Morphometric analysis was conducted on Trichrome-stained slides to quantitate the 
presence of collagen. Regions of interest for each slide were identified based on the presence of 
the same pulmonary structures. The quantity of collagen within the selected field was determined 
by computerized analysis of the intensity of blue-stained structures and expressed as a 
percentage of tissue area. 
Cav-1 Western Blot 
The lungs were collected from the animals upon euthanasia with an i.p. dose of 
pentobarbital sodium followed by exsanguination. The tissue specimens were immediately flash 
frozen in liquid nitrogen and stored at -80°C. The frozen specimens were then placed in 
homogenization buffer (0.1M Phosphate (PO4) pH 7.4 contained 1mM EDTA and 10µM 
indomethacin) and homogenized using a conventional rotor-stator homogenizer (Brinkmann 
Instruments, Westbury, NY) for 45-60sec until each sample was uniformly homogenous.  Sample 
protein concentration was determined using a BCA protein assay kit purchased from Pierce 
(Rockford, IL).  Based on protein concentration, homogenates were diluted to 20µg of 
protein/sample.  Each sample received SDS sample buffer containing 1M Tris-HCl (pH 6.8), 5% 
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(w/v) SDS, 2.5% (v/v) β-mercaptoethanol, 5% glycerol in double-distilled water and boiled to 
solubilize sample proteins. Boiled samples were subjected to SDS/PAGE, electrotransferred to a 
nitrocellulose membrane, and immunoblotted with Cav-1 and β-actin monoclonal antibodies 
from BD Biosciences (San Diego California). Bands were visualized using Super Signal West 
Pico Stable Peroxide and Luminol/Enhancer solutions (Pierce).  Densitometry analysis of blots 
and corresponding β-actin controls was performed using an imaging system (FOTO/Analyst 
Luminary Workstation, Fotodyne, Hartland, WI). The intensity of protein bands was analyzed by 
computerized densitometry (TotalLab TL-101 Image Analysis Software) and expressed as the 
ratio of the densitometric score measured for each target normalized by the β-actin control.   
Quantification of PGE2 by enzyme immunoassay (EIA) 
PGE2 was extracted from lung homogenates by solid phase extraction with C18 solid 
phase extraction cartridges (SPE Cartridges/C-18) purchased from Caymen Chemical (Ann 
Arbor, MI).  Post removal, lung tissue samples were flash frozen in liquid nitrogen and stored at 
-80°C. The frozen specimens were then placed in homogenization buffer (0.1M Phosphate (PO4) 
pH 7.4 contained 1mM EDTA and 10µM indomethacin) and homogenized using a bead beater.  
Homogenized samples were diluted 1:4 in homogenization buffer and the pH of samples was 
measured and adjusted to 4.0 using HCl.  pH adjusted samples were applied to the C18 cartridge 
(pretreated with methanol followed by HPLC grade water).  PGE2 was eluted from the cartridge 
with ethyl acetate containing 1% methanol.  Eluted samples in methanol were dried with a 
speedvac concentrator under vacuum and reconstituted with enzyme immunoassay (EIA) buffer 
from Caymen Chemicals (Ann Arbor, MI) for EIA measurement.  The concentration of PGE2 in 
lung homogenate samples were analyzed using a specific EIA kit from Caymen Chemicals (Ann 
Arbor, MI) according to manufacturer’s instructions.        
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Quantification of CysLT by enzyme immunoassay (EIA) 
cysLTs were isolated from long homogenates using  a cysLT Affinity Purification Kit 
from Caymen Chemicals (Ann Arbor, MI) per manufacturer’s instructions.  The concentrations 
of CysLTs in lung homogenates were evaluated using a specific EIA kit from Caymen 
Chemicals (Ann Arbor, MI) according to manufacturer’s instructions.    
Statistical Analysis 
All data were analyzed using a multivariate analysis of variance (ANOVA) for repeated 
measures. If a significant effect was found, a post-hoc t-test with Bonferroni correction was used 
to identify significant pairs. Individual comparisons were made using paired and unpaired t-test 
when appropriate (Sigmastat 2.0 for Windows, SPSS Inc., Chicago, IL). Values in the text and 
figures are presented as mean ± SE. Differences having a P value < 0.05 were considered 
significant. 
 
Experimental Protocols 
Specific Aim 1 & 2 
a) 5-Day Protocol. Adult rats (12 week-old) were infected with 100 µl of a suspension 
containing either high dose reovirus (2.5x106 PFU/µl; n=6) or low dose reovirus (7.5x102 
PFU/µl; n=6). Control animals (n=5) were inoculated with an equal volume of virus-free media. 
Weanling rats (2 week-old) were infected with 40 µl of a suspension containing either high dose 
reovirus (2.5x106 PFU/µl; n=5) or low dose reovirus (7.5x102 PFU/µl; n=6). Control animals 
(n=5) were inoculated with an equal volume of virus-free media. Five days after inoculation, the 
Evans Blue procedure was performed as previously described. The extra pulmonary airways 
(from the first tracheal ring to the end of the main stem bronchi) and the left lung were dissected 
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and prepared for Evans blue extraction. The right lung was removed for RNA extraction and 
histopathologic analysis. All animals were weighed before inoculation and after the 5-day 
incubation period. 
b) 30-Day Protocol. Adult rats (12 week-old) were infected with 100 µl of a suspension 
containing either high dose reovirus (2.5x106 PFU/µl; n=6) or low dose reovirus (7.5x102 
PFU/µl; n=6). Control animals (n=6) were inoculated with an equal volume of virus-free media. 
Weanling rats (2 week-old) were infected with 40 µl of a suspension containing either high dose 
reovirus (2.5x106 PFU/µl; n=6) or low dose reovirus (7.5x102 PFU/µl; n=6). Control animals 
(n=6) were inoculated with an equal volume of virus-free media. Thirty days after inoculation, 
the Evans Blue procedure was performed as previously described. The extra pulmonary airways 
(from the first tracheal ring to the end of the main stem bronchi) and the left lung were dissected 
and prepared for Evans blue extraction. The right lung was removed for RNA extraction and 
histopathologic analysis. All animals were weighed before inoculation and after the 30-day 
incubation period. 
Specific Aim 3 
5-Day protocol: Weanling rats (2 week-old) were infected with 40 µl of a suspension 
containing either high dose reovirus (2.5x106 PFU/µl; n=2) or low dose reovirus (7.5x102 
PFU/µl; n=2) and control animals (n=2) were inoculated with an equal volume of virus-free 
media.  At 5 days post inoculation rats were anesthetized with Pentobarbital sodium (25mg/kg 
i.p.).  Blood samples were taken prior to sacrifice.  Lungs were inflated with .5 to 1.5 ml of 
formalin using a 16 gauge cannula attached to a syringe and allowed to sit for 5 minutes prior to 
removal.  The right lung was dissected and prepared for histopathologic analysis.  The left lung 
was removed for RNA, protein  and hormone analysis.   
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60-Day protocol: Weanling rats (2 week-old) were infected with 40 µl of a suspension 
containing either high dose reovirus (2.5x106 PFU/µl; n=2) or low dose reovirus (7.5x102 
PFU/µl; n=3).  Control animals (n=3) were inoculated with an equal volume of virus-free media.  
At 60 days post inoculation rats were anesthetized with Pentobarbital Sodium (25mg/kg i.p.).  
Blood samples were taken prior to sacrifice.  Lungs were inflated with .5 to 1.5 ml of formalin 
using a 16 gauge cannula attached to a syringe and allowed to sit for 5 minutes prior to removal.  
The right lung was dissected and prepared for histopathologic analysis.  The right lung was 
removed for RNA, protein and hormone analysis.  
90-Day protocol: Weanling rats (2 week-old) were infected with 40 µl of a suspension 
containing either high dose reovirus (2.5x106 PFU/µl; n=2) or low dose reovirus (7.5x102 
PFU/µl; n=3).  Control animals (n=2) were inoculated with an equal volume of virus-free media.  
At 90 days post inoculation rats were anesthetized with Pentobarbital Sodium (50mg/kg i.p.).  
Blood samples were taken prior to sacrifice.  Lungs were inflated with .5 to 1.5 ml of formalin 
using a 16 gauge cannula attached to a syringe and allowed to sit for 5 minutes prior to removal.  
The right lung was dissected and prepared for histopathologic analysis.  The right lung was 
removed for RNA, protein and hormone analysis.  
120-Day protocol: Weanling rats (2 week-old) were infected with 40 µl of a suspension 
containing either high dose reovirus (2.5x106 PFU/µl; n=2) or low dose reovirus (7.5x102 
PFU/µl; n=3).  Control animals (n=2) were inoculated with an equal volume of virus-free media.  
At 120 days post inoculation rats were anesthetized with Pentobarbital Sodium (50mg/kg i.p.).  
Blood samples were taken prior to sacrifice.  Lungs were inflated with .5 to 1.5 ml of formalin 
using a 16 gauge cannula attached to a syringe and allowed to sit for 5 minutes prior to removal.  
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The right lung was dissected and prepared for histopathologic analysis.  The right lung was 
removed for RNA, protein and hormone analysis.  
Results 
HISTOPATHOLOGY AND MORPHOMETRIC ANALYSIS 
Weanlings  
H&E stained microscopic lung sections from weanling rats sacrificed 5 days post 
inoculation were analyzed to determine the inflammatory response to reovirus and how it is 
augmented by virus dose.  Rats infected with high dose reovirus developed multifocal and 
coalescent, acute, suppurative and lymphocytic bronchopneumonia.  The grade of 
bronchopneumonia was described as moderate to acute.  Features of the pneumonia included the 
accumulation of neutrophils in the alveolar region, intraluminal accumulation of mucus in 
bronchioles, and peribronchiolar and perivascular accumulation of mononuclear inflammatory 
cells (Figure 11-A & Figure 12-A).  In comparison, the Low dose reovirus resulted in a milder 
multifocal, lymphocytic, bronchopneumonia.  Features of the pneumonia included the 
peribronchiolar and perivascular accumulation of mononuclear inflammatory cells that were 
predominantly lymphocytes (Figure 11-B Figure 12-A).  Control animals demonstrated no 
significant findings. 
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Figure 11 Histological features of reovirus induced pneumonia at 5 and 30 days post infection 
Electron micrographs of H&E stained lung sections from weanling rats infected with either 2.5x106 PFU/µl (High dose) or 
7.5x102 PFU/µl (Low dose) of reovirus T1/L at 40 x magnifications. A) The accumulation of polymorphonuclear cells (PMNs) 
in the alveolar spaces (yellow arrows), perivascular accumulation of mononuclear inflammatory cells, intralumenal accumulation 
of mucous in bronchioles, and peribronchiolar influx of neutrophils was apparent in lung sections from rats  5 days post infection 
with high dose reovirus. B)Low dose virus infection resulted in peribronchiolar and perivascular accumulation of mononuclear 
inflammatory cells (yellow arrows) at 5 days post infection. C) PMNs (yellow arrows) and chronic inflammatory cells were seen 
within the bronchioles and the interstitium at 30 days post infection with high dose virus.  Mucus and necrotic cellular debris was 
also noted in bronchiole spaces as well as foamy macrophages (red arrows). D)Low dose reovirus infection resulted in mild 
chronic peribronchiolar inflammation.  Features included mild, multifocal, mucous metaplasia, presence of chronic inflammatory 
cells in the interstitium and around respiratory bronchioles, with foamy macrophages being seen as well (red arrow). 
At 30 days post inoculation rats infected with high dose virus exhibited moderate chronic 
inflammation that was focused around respiratory bronchioles.  Inflammatory features included 
the presence of PMNs and chronic inflammatory cells within the bronchioles and the interstitium 
(Figure 12-A).  Mucus and necrotic cellular debris was also found in bronchiole spaces along 
with foamy macrophages (Figure 11-C).  In a few samples, occasional bronchioles contained 
detached epithelial cells associated with faint cytoplasmic vacuoles and basophilic foci, which 
could be representative of viral inclusions.  Low dose reovirus infection resulted in mild chronic 
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peribronchiolar inflammation.  Features included mild, multifocal, mucus metaplasia, presence 
of chronic inflammatory cells in the interstitium and around respiratory bronchioles (Figure 12-
A).    Moderate, multifocal, medial hypertrophy of pulmonary arterioles was also identified and 
specific to low dose virus infection.     
 
Figure 12 Histological features of reovirus induced pneumonia in adult and weanling rats 
Electron micrographs of H&E stained lung sections from weanling rats infected with either 2.5x106 PFU/µl (High dose) or 
7.5x102 PFU/µl (Low dose) of reovirus T1/L at 40 x magnifications. A) H&E-stained microscopic sections of weanling rat lungs 
obtained 5 and 30 days following inoculation with either low or high dose reovirus or pathogen-free vehicle. At 5 days post-
infection, lung sections from rats infected with either dose of reovirus, show acute cellular infiltrates consisting mainly of 
neutrophils, monocytes and mast cells consistent with moderate to severe interstitial and peribronchial inflammation compared to 
control animals. At 30 days the acute histopathologic changes were completely resolved and no significant differences were 
observable between treated and virus-free animals. Images are representative of 6 animals. B) H&E-stained microscopic sections 
of adult rat lungs obtained 5 and 30 days post inoculation. Five days following infection with either dose of reovirus, the animals 
developed an acute inflammatory response characterized by the presence of moderate to severe acute peribronchial and interstitial 
cellular infiltrates comprised of neutrophils and monocytes which was associated with mild hyperplasia of bronchus-associated 
lymphoid tissue (BALT). These changes were lost at 30 days post inoculation as shown by the lack of any inflammatory cells in 
either virus-infected or pathogen-free animals. Images are representative of 6 animals. 
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Trichrome stained microscopic lung sections from weanling rats 30 days post reovirus 
infection were analyzed for changes in collagen deposition in response to reovirus infection.  
Overall, reovirus infected weanlings exhibited signs of increased collagen accumulation 
associated with the early stages of fibrosis development at 30 days post infection.  High dose 
reovirus infection resulted in focal, mild fibrosis (Figure 13-A).  Fibrotic regions demonstrated 
decreased vascular perfusion in conjunction with increases in epithelial cells.  Areas 
demonstrating intensified blue staining exhibited augmented collagen accumulation associated 
with increased numbers of fibroblasts in terminal respiratory bronchioles and alveolar spaces of 
the interstitium suggestive of interstitial fibrosis.  Low dose reovirus infection resulted in a 
similar pathology of focal, mild fibrosis (Figure 13-A).  Overall, the Trichrome-stained 
microscopic sections of weanling rat lungs 30 days after infection, showed signs of collagen 
accumulation which was graded as mild fibrosis. 
 Computerized morphometric analysis of lung sections showed a small, yet significant 
increase of collagen content in the lungs of low dose treated rats compared to controls (Figure 
13-B) with a p value < 0.05.  A more robust increase in collagen was seen in response to high 
dose virus infection as demonstrated by a more significant increase in collagen content in 
infected rats compared to controls with a p value < 0.001.  These changes were not observed in 
any of the animals 5 days after infection. 
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Figure 13 Trichrome Staining and Morphometric Analysis 
A) Masson’s Trichrome-stained weanling rat lung sections obtained 30 days after inoculation with either dose of reovirus or 
virus-free vehicle. An increased degree of collagen deposition was observed in infected rats compared to age-matched pathogen-
free controls as indicated by a more significant blue staining Images are magnified 20x and are each representative of 6 animals.  
B) The computerized morphometric analysis of the same lung sections showed a significantly higher collagen deposition in 
treated animals compared to controls. This effect appears to be dose-dependent. Data are expressed as %collagen/ tissue area and 
are mean +/- SE (n=6; ***p<0.001; *p<0.05; ANOVA with Fisher LSD post-hoc analysis). 
At 60 days post inoculation rats infected with either reovirus dose exhibited mild focal 
chronic inflammation (Figure 14).  Chronic inflammation was mainly focused on respiratory 
bronchioles.  Germinal centers around airway spaces were observed.  No acute inflammatory 
cells were observed, but a few foamy macrophages were seen in the lumen of terminal 
respiratory bronchioles.  Trichrome staining revealed focal increases in collagen deposition as 
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well as a thickening of alveoli septa.  Increased number of fibroblasts associated with respiratory 
bronchioles was noted. 
 
 
Figure 14 Histology at 60 days post infection 
Electron micrographs of lung sections from weanling rats infected with either 2.5x106 PFU/µl or 7.5x102 PFU/µl of reovirus 
T1/L at 20× magnification.H&E and Trichrome stained microscopic sections of rat lungs obtained 60 days post inoculation.  
Chronic inflammation was mainly focused on respiratory bronchioles.  Germinal centers around airway spaces are observed.  No 
acute inflammatory cells were observed, but a few foamy macrophages were seen in the lumen of terminal respiratory 
bronchioles.  
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Adults  
Five days post reovirus infection, H&E-stained microscopic sections demonstrated acute 
peribronchial and interstitial cellular infiltrates made of neutrophils and monocytes which were 
graded moderate to severe (Figure 12). In addition, the presence of locally extensive, mild 
hyperplasia of bronchus-associated lymphoid tissue (BALT) was noted (Figure 15). These 
inflammatory cellular infiltrates were minimal or absent 30 days post reovirus infection (Figure 
12). The lungs of control rats showed minimal or no pathologic changes. No significant 
differences were observed in the severity of pathologic changes between rats infected with high 
or low dose reovirus.  
 
Figure 15 Adult Rat Bronchus-associated Lymphoid Tissue (BALT) 
H&E stained microscopic sections of adult rat lungs 5 days post reovirus infection.  Locally extensive, mild hyperplasia of BALT 
was associated with reovirus infection.  Low dose infection results in the expansion of BALT as demonstrated by the increased 
infiltration by inflammatory cells into the bronchiole epithelium and interstitium.  High dose induced a similar hyperplasia with 
accumulations of lymphoid cells and formation of lymphoid follicles in the interstitium that expanded into the bronchiole lumen.  
Both low and high dose showed active germinal centers. 
Body Weight 
In order to further document the pathologic effect of the virus, we measured the average 
weight gain between inoculation and the end of incubation time, immediately before performing 
the vascular extravasation procedure. Weight gain was significantly reduced in weanling rats five 
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days after infection compared to controls. Weight gain was unaffected at 30 days post infection 
as well as in treated and control adult rats at 5 and 30 days (Figure 16).  
 
Figure 16 Acute Changes in Body Weight Demonstrate Reovirus Pathology 
A) Weanlings failed to gain weight during the 5 days following infection with either low or high reovirus dose compared to their 
age-matched pathogen-free controls. Data are expressed as the average weight gain (% compared to pre-treatment value) and are 
indicated as mean ± SE (n=6; ***p<0.001; ANOVA with Fisher LSD post-hoc analysis). B) The growth rate was restored during 
the 30 days after reovirus infection and was comparable to pathogen-free controls. Data are expressed as the average weight gain 
(% compared to pre-treatment value) and are indicated as mean ± SE (n=6; ***p<0.001; ANOVA with Fisher LSD post-hoc 
analysis). C) In adult rats, at 5 days post infection, no significant changes in weight gain were observed in infected rats compared 
to pathogen-free controls. Data are expressed as the average weight gain (% compared to pre-treatment value) and are indicated 
as mean ± SE (n=6; p=ns; ANOVA).  D) In adult rats, at 30 days post infection, no significant changes in weight gain were 
observed in infected rats compared to pathogen-free controls. Data are expressed as the average weight gain (% compared to pre-
treatment value) and are indicated as mean ± SE (n=6; p=ns; ANOVA).  
Vascular Permeability 
In adult rats, Evans blue-labeled albumin extravasation from extra pulmonary and intra 
pulmonary airways was significantly increased 5 days after inoculation compared to age-
matched controls (Figure 17-C). The magnitude of the increase was not significantly different 
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between high and low dose reovirus-treated animals.  This effect was still significant 30 days 
after infection in the animals treated with the higher dose only (Figure 17-D).  
In weanling rats, vascular extravasation from the lung was significantly larger in low 
dose infected rats compared to controls (Figure 17-A).  Evans-blue labeled extravasation from 
the trachea was unaffected at 5 days. These effects were lost 30 days after reovirus infection 
(Figure 17-B).  
 
Figure 17 Changes in Vascular Permeability indicative of Neurogenic Inflammation 
A) Extravasation of Evans blue-labeled albumin from the airway microvasculature in weanling rats following inoculation with 
either low or high dose reovirus or pathogen-free vehicle. In the intrapulmonary airways, vascular extravasation was significantly 
higher in infected animals compared to pathogen-free controls. This effect appears to be dose-related and is lost 30 days after 
inoculation. The extrapulmonary airway vessels were unaffected. Data are expressed as mean ± SE (n=5-6; ***p<0.001 vs 
controls and low dose; #p<0.001 vs controls and high dose; ANOVA with Fisher LSD post-hoc analysis). B) Vascular 
extravasation in the intrapulmonary and extrapulmonary airway microcirculation of adult rats 5 and 30 days after treatment with 
either dose of reovirus or pathogen-free vehicle. At 5 days post inoculation the quantity of Evans blue-labeled albumin recovered 
from the extrapulmonary airway micro vessels was significantly higher in infected rats compared to pathogen-free controls. No 
differential effects were observed between low and high reovirus dose. In animals infected with high dose reovirus, the increased 
vascular permeability was still significantly higher in treated animals compared to controls 30 days post reovirus infection. Data 
are expressed as mean ± SE (n=5-6; ***p<0.001; ANOVA with Fisher LSD post-hoc analysis).  
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Neurotrophin Expression 
Protein Expression 
In order to determine if the changes in vascular extravasation seen in response to reovirus 
infection were mediated by neurogenic mechanisms we analyzed the protein expression of 
BDNF and NGF.  In weanling rats NGF protein expression (Figure 18-B) was increased in 
control and low dose animal at 5 days post infections when compared to high dose animals 
which showed diminished NGF.  These differences were not significant.  The amount of NGF 
protein decreased at 30 days and was not affected by virus infection with all experimental groups 
showing similar expression.  BDNF in weanling rats showed no significant changes at 5 and 30 
days post infection, though there were higher levels of BDNF post viral clearance (Figure 18-A).  
In adult rats the amount of NGF (Figure 18-D) and BDNF (Figure 18-C) protein was unaffected 
by reovirus infection at both 5 and 30 days.  
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Figure 18 Neurotrophin Protein Expression at 5 & 30 days 
The amount of NGF and BDNF protein in rat lung homogenates were analyzed by ELISA at 5 and 30 days post infection.  A) 
BDNF protein in weanling rats showed no significant changes at 5 and 30 days post infection. B) NGF protein expression in 
weanling rats at 5 days post infection with low and high dose reovirus demonstrated increased amounts of NGF protein.  The 
amount of NGF protein decreased at 30 days and was not affected by virus infection. C) Expression of BDNF protein in adult rats 
was unaffected at 5 and 30 days post infection in all experimental groups. D) Expression of NGF protein in adult rats was 
unaffected at 5 and 30 days post infection in all experimental groups.  Data are expressed as mean ± SE (n=5-6; ANOVA with 
Fisher LSD post-hoc analysis).  
mRNA Expression 
The expression of the neurotrophins NGF, BDNF and the receptors TrKb and p75 in lung 
homogenates as measured by mRNA levels (RT-PCR) did not reveal any significant changes in 
response to reovirus infection at 5 (Figure 19-A) and 30 days (Figure 19-B) in weanling rats.  
The expression of NGF and BDNF was significantly decreased in reovirus treated adult rats at 5 
days post infection, while receptor expression was not affected (Figure 19-C).  The changes in 
NGF and BDNF were no longer present at 30 days post infection and receptor expression 
continued to be unaffected (Figure 19-D).      
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Figure 19 mRNA Expression of Neurotrophins and their Receptors 
A) The semiquantitative RT-PCR analysis of NGF, BDNF, NGF high affinity receptor (TrKa), NGF low affinity receptor (p75), 
and BDNF receptor (TrKb) mRNA products in lung tissues of weanling rats 5 and 30 days after inoculation with either low or 
high reovirus dose or virus-free vehicle did not reveal any significant changes. The amplified RT-PCR products were analyzed 
by electrophoresis on an ethidium bromide-stained 2% agarose gel. The gel was photographed and the intensity of the DNA 
bands was analyzed by computerized densitometry. Data are expressed as the ratio of the densitometric score measured for each 
target normalized by the β-actin control and are mean +/- SE (n=5-6; p=ns; ANOVA).  B) The same analysis performed on adult 
rats lung homogenates 5 days after reovirus infection revealed a decreased expression of NGF and BDNF in infected rats 
compared to pathogen-free controls, whereas NGF high affinity receptor (TrKa) and low affinity receptor (p75) and BDNF 
receptor (TrKb) were unaffected. These changes were lost 30 days post reovirus infection. The amplified RT-PCR products were 
analyzed by electrophoresis on an ethidium bromide-stained 2% agarose gel. The gel was photographed and the intensity of the 
DNA bands was analyzed by computerized densitometry. Data are expressed as the ratio of the densitometric score measured for 
each target normalized by the β-actin control and are mean +/- SE (n=5-6; *p<0.05; ANOVA with Fisher LSD post-hoc analysis). 
Caveolin-1 Protein Expression 
The effect of reovirus pulmonary infection on the expression of cav-1 was determined by 
western blot analysis.  The expression of cav-1 protein at 5 days post infection was decreased in 
reovirus samples compared to controls (Figure 20-A).  Statistical analysis determined that this 
decrease was not significant.  At 30 days post infection Cav-1 protein expression was 
inconsistent, showing decreased and increased expression in response to reovirus infection 
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(Figure 20-B).   The magnitude of change in cav-1 expression was not dependent on the virus 
dose, but rather it was dependent upon the presence of fibrosis.  Statistical analysis of samples 
exhibiting mild fibrosis as determined by a pathologist demonstrated significant decreases in 
cav-1 expression compared to controls (figure 20-D).  In comparison, statistical analysis of 
samples exhibiting minimal to no signs of fibrosis in response to reovirus showed insignificant 
increased cav-1 expression compared to controls (Figure 20-E).  At 60 days post infection, cav-1 
expression appeared to decrease in response to virus infection when compared to controls 
(Figure 20-C), but was not significant.  At 120 days cav-1 expression was not altered in 
comparison to controls (Figure 20-C).  
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Figure 20 Analysis of Cav-1 Protein Expression post reovirus infection 
A) Cav-1 protein expression at 5 days post infection was decreased in reovirus infected samples (indicated by +) compared to 
controls (as indicated by -) as determined by immunoblot analysis of lung homogenates.  Β-actin serves as a loading control.  
B)Cav-1 expression at 30 days post infection was varied  , with some samples showing decreased expression and othesr 
demonstrating increased expression in response to reovirus infection (indicated by +) compared to controls (indicated by -).  C) 
Cav-1 expression over the full time course, 5-120 days post infection as determined by immunoblot analysis using β-actin as a 
loading control.  D) The expression of cav-1 in homogenates from rats lungs that were determined by hitological analysis to have 
significant fibrosis showed a significant decrease in cav-1 protein expression when compared to controls.  Data are expressed as 
the ratio of the densitometric score measured for each target normalized by the β-actin control and are mean +/- SE (n=6; 
*p<0.05; ANOVA with Fisher LSD post-hoc analysis).  E) Expression of cav-1 in samples from rats demonstrating less 
pronounced fibrosis in response to reovirus infection showed insignificant differencse in expression between reovirus infected 
samples and controls.  The intensity of the protein bands was analyzed by computerized densitometry. Data are expressed as the 
ratio of the densitometric score measured for each target normalized by the β-actin control and are mean +/- SE (n=6; *p<0.05; 
ANOVA with Fisher LSD post-hoc analysis). 
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Concentration of PGs and LTs  
In order to determine the effect of reovirus infection on the synthesis of PGE2 and LTs in 
the airway we measured the concentration of each by enzyme immunoassay (EIA) at each time 
point (Figure 21-A).  At 5 days post infection, the concentration of PGE2 was similar in the lungs 
of control and reovirus infected rats.  PGE2 concentration diminished in response to reovirus 
infection compared to controls at 30 days.  The difference in the median lung PGE2 
concentrations between virus doses was minimal.  At 60 days post infection the concentration of 
PGE2 in virus infected rats was diminished in response to both low and high dose infection when 
compared to controls, with high dose infected rats exhibiting the largest decrease in 
concentration.  At 90 days post infection the amount of PGE2 was increased in reovirus infected 
rats, with high dose infection showing the greatest increase.  At 120 days post infection PGE2 
was decreased in control and low dose reovirus infected rats.  In comparison rats infected with 
high dose demonstrated greater PGE2 levels.  Statistical analysis revealed that all changes in 
concentration were not significant.   
Reovirus infected rats’ demonstrated increased amounts of LTs in the airway compared 
to controls at 5 days post infection (Figure 21-B).  Changes in the concentration of airway LTs 
were no longer present at 30 days.  LT concentration continued to be similar between the three 
experimental groups at 60 days post infection.  At 90 days post infection the amount of LTs in 
the airway increased in high dose infected animals compared to both control and low dose.  
Increased LT synthesis in both low and high dose reovirus infected rats continued at 120 days 
post infection when compared to controls.  Though there were apparent differences between 
experimental groups, there were no significant differences between groups.     
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Figure 21 Expression of the hormones PGE2 and LT in response to reovirus infection 
A) Concentration of LTs in lung homogenates from control and reovirus infected rats at 5, 30, 60, 90 and 120 days post infection 
were analyzed by using a specific enzyme immunoassay technique.  Changes in LT concentration were not significant between 
experimental groups.  Data represents the mean +/- SE (n=5-6; ANOVA with Fisher LSD post-hoc analysis).  B) Expression of 
PGE2 in lung homogenates from control and reovirus infected rats at 5, 30, 60, 90 and 120 days post infection were analyzed by 
using a specific enzyme immunoassay technique.  Changes in PGE2 expression were not significant between experimental 
groups.  Data represents the mean +/- SE (n=5-6; ANOVA with Fisher LSD post-hoc analysis). 
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CHAPTER 5 
Discussion 
Reovirus and Neurogenic Inflammation 
Viral respiratory infections early in life have a significant impact on the developing 
airway resulting in pathogenic long term effects such as asthma and fibrosis.  Viral induced 
dysregulation of the airway’s neuroimmune interactions by RSV have been shown to result in 
airway hyper reactivity from potentiated neurogenic inflammation in response to augmented 
NGF and trkA expression.  In this study, we used another common early life pathogen, reovirus, 
in a rat model of airway inflammation to reveal its effects on the airway’s physiological 
responses.  Our data show that acute reovirus LRTI in adult (12 week-old) and weanling (2 
week-old) rats results in short term potentiation of neurogenic-mediated inflammation that 
coincides with acute inflammatory responses.  This was indicated by the increased microvascular 
permeability following stimulation of capsaicin-sensitive sensory nerves 5 days after virus 
inoculation. This effect is lost in weanling rats 30 days after infection, but is still present in adult 
rats treated with high dose reovirus. The intrapulmonary and extra pulmonary airway responses 
were differentially affected in the two age groups as demonstrated by the differences in Evans-
blue labeled albumin extravasation in response to capsaicin.  In weanling rats, the potentiation of 
capsaicin-induced neurogenic inflammation was significant in the lung or intrapulmonary 
airways, but not in the extra pulmonary airways of infected animals at only the 5 day time point. 
In adult rats, this effect was significant in both the extra pulmonary and intrapulmonary airways 
and was present at both 5 and 30 days. The age-related differential sensitivity of intra- and extra 
pulmonary airways to viral infection is consistent with previous observations in rats infected 
with RSV [295, 301] and reflects the developmental modification in the anatomic distribution of 
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sensory nerve fibers across the respiratory tract [298, 302]. However, unlike RSV, reovirus did 
not result in potentiation of neurogenic inflammation at 30 days in weanling rats.  Nonetheless, 
our data are the first to document such a physiological response in the airways of rats following 
lower respiratory tract infection with reovirus, suggesting that other viral pathogens can cause 
neurogenic inflammation.  
Potentiation of neurogenic inflammation was observed in adult rats that received high 
dose virus leading to the hypothesis that viral dose may be a critical factor in potentiating 
neurogenic inflammation. More specifically, increasing severity of infection in response to 
higher doses of reovirus may directly correlate with increases in remodeling to airway 
innervations.  In order to determine if higher doses of reovirus could induce potentiated 
neurogenic inflammation further studies infecting rats with a titer of reovirus greater then 
2.5x106 PFU/µl would have to be done.  This may be difficult in weanling rats since both high 
and low dose reovirus resulted in significant weight loss indicative of a severe infection, but may 
be possible in adult rats.  Measuring the Evans-blue labeled albumin extravasation in response to 
a higher dose of reovirus could indicate whether or not potentiation of neurogenic inflammation 
is dose dependent.  Furthermore, infection severity as determined by histolopathologic analysis 
and measurement of body weight in response to a higher dose of reovirus could provide a 
correlation between severity and changes in airway innervations. 
Another important component that could be involved in reovirus induced changes to 
neurogenic inflammatory responses is neutral endopeptidase (NEP).  NEP is a membrane bound 
metalloproteinase that exists at the surface of AECs, SMCs, sub mucosal gland cells and 
fibroblasts.  The key role of NEP is to limit the actions of the sensory peptides known as 
tachykinins, such as SP, that provoke neurogenic inflammation.  It preferentially cleaves SP into 
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inactive fragments that lack the carboxyl terminal region that is necessary for the binding to NK-
1.  Therefore, NEP activity is responsible for preventing SP induced exaggerated neurogenic 
inflammation.  Studies have shown viral infection, and exposure to air pollutants and allergens 
are able to reduce NEP activity [303]. We speculate that reovirus infection destabilizes the 
integrity of the airway epithelium by either directly affecting epithelial cells or indirectly by 
inducing the production of detrimental inflammatory factors resulting in reduced NEP activity.  
As a result of reduced NEP, SP is able to induce exaggerated neurogenic inflammation during 
acute infection (5 days).  At the cessation of acute inflammation (30 days) the detrimental factors 
are no longer present and the integrity of the airway epithelium returns as does the normal level 
of NEP activity.  Reinstated NEP activity removes any excess SP, preventing an exaggerated 
neurogenic inflammatory response.  The severity of infection is important in controlling the 
amount of damage or injury to the epithelium and could be the determining factor in whether or 
not changes in NEP can be returned to normal or become a chronic condition.  Higher doses of 
reovirus could produce a more severe LRTI characterized by more significant injury to the 
airway epithelium, resulting in chronic reduced NEP activity.  Persistent decreased NEP explains 
the potentiation of neurogenic inflammation in adult rats 30 days post infection with high dose 
reovirus.  Therefore, higher doses of virus produce more severe LRTIs that can permanently 
switch the neurogenic airway responses from protective to detrimental, resulting in perpetuated 
and augmented airway inflammation.   
Previous work has shown that the potentiation of neurogenic inflammation observed 
during acute infection with RSV is associated with up regulation of the neurotrophin NGF and its 
high and low affinity receptors (TrKa, and p75) which, in turn, controls the expression of the 
gene encoding the peptide neurotransmitter SP  resulting in the increased release of this 
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neuropeptide from airway sensory nerves [292].  It also induces increased expression of the SP 
high affinity receptor NK-1 in the airway, further contributing to exacerbating the neurogenic 
inflammatory response.   In our study, we did not observe any significant changes in the 
expression of the neurotrophins NGF and BDNF as well as their receptors in weanling rats 
following reovirus infection, but we did observe a significant decrease in NGF and BDNF 
expression in adult rats at 5 days but not 30 days.   Our findings, therefore, suggest a different 
mechanism that is not associated with NGF-driven up regulation of SP and NK-1 expression is 
responsible for reovirus induced neurogenic inflammation.  Therefore, our results demonstrate 
that reovirus produces augmented neurogenic inflammation that is mediated by SP and NK-1 but 
the mechanism responsible for the change is not clear.   
SP is one of the most effective and versatile inflammatory mediators known. It greatly 
increases endothelial permeability and blood flow in post capillary venules, causing airway 
edema; stimulates the proliferation and activation of T and B lymphocytes; attracts leukocytes to 
the vascular endothelium; causes degranulation of MCs with release of other mediators of 
inflammation; and primes and activates monocytes and macrophages to release a variety of 
cytokines such as TNF-α and IL-6 [304-310].  Receptors for SP have been identified in all these 
and various other cell types in humans.  Although SP has been described as a peptide of neuronal 
origin, research has shown it is also produced by inflammatory cells such as macrophages, DCs 
and lymphocytes, during inflammation [308, 310-311]. In addition, augmented neurogenic 
inflammation that is mediated by SP was mainly associated with acute infection and 
inflammation, indicating that components of the inflammatory response to reovirus may act as 
regulatory mediators.  Therefore, one possible hypothesis is that reovirus infection induces 
increased SP production and NK-1 expression by inflammatory cells resulting in augmented 
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acute neurogenic inflammation.  These changes are not potentiated because of the decreased 
presence of inflammatory cells at the chronic stage (30 days) of infection.  Our results indicate 
that the acute inflammatory response to reovirus infection results in increased infiltration of the 
alveolar interstitium by inflammatory cells, specifically macrophages, PMNs and lymphocytes.  
The infiltrating inflammatory cells present at 5 days could serve as the source of increased SP 
that exacerbates the inflammatory processes and enhances neurogenic inflammation.   At 30 days 
the population and number of inflammatory cells present in the alveolar interstitium is altered, 
with a decreased number of infiltrating cells that consist of lymphocytes and few to no acute 
inflammatory cells resulting in a less robust SP response to capsaicin and no potentiation of 
neurogenic inflammation at 30 days.  However, in the present study, the capacities of infiltrating 
inflammatory cells in reovirus-induced airway responses were not investigated.  
Reovirus and Inflammation 
The acute changes in vascular permeability coincided with increased inflammatory cell 
infiltration into the respiratory bronchioles and alveolar spaces of rat lungs 5 days post infection.  
The peribronchiolar and perivascular accumulation of inflammatory cells such as lymphocytes 
and neutrophils was consistent with previous observations in rodents [7].  At 30 days post 
infection, chronic inflammatory cells were observed in the bronchiole spaces and the interstitium 
of virus infected rats. The presence of neutrophils and faint cytoplasmic vacuoles and basophilic 
foci associated with viral inclusion was observed in and specific to high dose reovirus infection.  
This indicated that the virus dose may have an effect on the long term inflammatory responses.  
However, there were no observed histological differences between the two virus doses at 60 days 
post infection.  Both doses resulted in continued chronic inflammation around respiratory 
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bronchioles along with a few foamy macrophages in the lumen of terminal respiratory 
bronchioles.   
Reovirus and Fibrosis  
The early signs of fibrosis development were observed in reovirus weanling rats 30 days 
post reovirus infection as demonstrated by increased collagen accumulation and increased 
fibroblast localization to respiratory bronchioles and alveolar spaces.  Reovirus infection resulted 
in focal, mild fibrosis.  Fibrotic regions demonstrated decreased vascular perfusion in 
conjunction with increases in epithelial cells and fibroblasts.  These regions were located in the 
interstitial spaces and were associated with increases in collagen and number of fibroblasts being 
found, specifically at terminal respiratory bronchioles and alveolar spaces, suggesting interstitial 
fibrosis.  These results are unique to reovirus and have not been observed in response to other 
early life pathogens such as RSV.  This demonstrates that early life reovirus infection may be a 
potential risk or initiating factor for remodeling of the airway.   
Our preliminary results demonstrated that cav-1 may be a relevant influential factor in the 
pathogenesis of reovirus induced airway remodeling.  The expression of cav-1 protein was not 
consistent, but varied between rats and time points, providing contradictory results.  Samples 
from rats that demonstrated significant fibrosis at 30 days exhibited decreased cav-1 protein 
expression, while samples from rats demonstrating less pronounced fibrosis showed cav-1 
expression that was either equivalent to or greater than controls.  This correlates with previous in 
vitro and in vivo studies of bleomycin induced fibrosis as well as observations of IPF lung 
samples where cav-1 expression is decreased, indicating cav-1 is anti-fibrogenic.  Previous 
studies did not look at time points past 30 days, but we observed at 60 days post infection, cav-1 
expression appeared to decrease in response to virus infection when compared to controls, but 
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this observation is based on a limited sample size of 2.  Such a limited sample size does not 
depict a realistic or significant collection for analysis.  Increasing the number of samples would 
provide a more comprehensive representation of the changes induced by reovirus infection and 
would allow us to determine whether the changes observed could be statistically significant.  
Interestingly, at 120 days cav-1 expression was not altered in comparison to controls, but again 
we had a very small sample size of 1 control and 2 reovirus infected rats.  Therefore, repeating 
this experiment would provide a larger samples size that would allow for more useful and 
informative analysis.  However, this experiment did provide the important observation that cav-1 
expression at 30 days is significantly decreased in fibrotic samples. We speculate that reovirus 
LRTI decreases airway cav-1 expression, reversing the inhibition of profibrogenic processes 
resulting in the development of fibrosis.  It has been well documented in previous studies that 
TGF-β signaling can serve as a primary stimulus for fibrogenic processes such as fibroblast 
activation and synthesis of ECM [46-48].  More importantly, it has also been determined that the 
cav-1 is a key regulator in TGF-β profibrogenic signaling (Figure 6), inhibiting the activation of 
key signaling cascades and therefore preventing fibrogenic processes [102].  Based on this, we 
suppose a mechanism for reovirus induced fibrosis where decreased cav-1 expression results in 
increased TGF-β profibrogenic signaling and the development of fibrosis.  Further investigation 
is needed in order to determine if TGF-β is influential in the pathogenesis of reovirus induced 
fibrosis.  Primarily, it would be necessary to look at TGF-β expression at both the protein and 
transcriptional level to determine if its activity is altered by reovirus LRTI.  Nonetheless, our 
results demonstrate that cav-1 expression is altered post reovirus infection and could be relevant 
in the mechanisms responsible for reovirus induced fibrosis.   
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Eicosanoids have been implicated as key mediators in the development of 
fibropriliferation in other fibrotic diseases.   Our results demonstrate that neither PGE2 nor LTs 
are involved in the pathogenesis of reovirus induced fibrosis, as implicated by no changes in the 
synthesis of either hormone in response to reovirus LRTI.  The method used for the 
quantification of both PGE2 and the LTs was imprecise, as demonstrated by the large significant 
error between samples. Increasing the number of samples would allow for more precise 
calculations of PGE2 and LT sample concentration.  Further investigation using other methods of 
analysis could demonstrate whether or not PGs and/or LTs are influential in reovirus induced 
fibrosis.  One means of investigating this would be to observe the activity of the enzymes 
involved in their synthesis.  Analysis of COX-2 transcription would indicate changes in the level 
of PGE2 synthesis, based on the fact that COX-1 is constitutively expressed and COX-2 
expression is only present during periods of increased PG synthesis.  Therefore, changes in 
COX-2 transcription would be indicative of increased PGE2.  Analysis of 5-LO transcription 
would provide similar information about the level of LT synthesis.  A second means of 
investigating the involvement of both hormones would be to inhibit their synthesis or receptor 
binding and observe if changes in fibrotic development occur.  Nonetheless, we concluded from 
our data that eicosanoids do not play an influential role in the pathogenesis of reovirus induced 
fibrosis.      
Conclusion 
In conclusion, our data show that reovirus, a commonly occurring airway pathogen, 
causes acute neurogenic-mediated airway inflammation which, unlike RSV, is not associated 
with the NGF-mediated disruption of neurosensory airway innervations. In weanling rats these 
physiological responses are associated with the development of mild pulmonary fibrosis and, 
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therefore indicate the potential for long-lasting sequelae.   Regulation of reovirus induced 
fibrosis may be influenced by cav-1 expression, but does not involve the eicosanoids.  Additional 
studies are necessary to investigate the mechanisms involved in the reovirus-induced airway 
responses and whether they represent potential risk factors for the development of airway 
diseases.  Taken together this reports that early life reovirus LRTI has both acute and long term 
effects on airway physiology that results in acute augmentation of airway neurogenic 
inflammation and subsequent development of fibrosis that is mediated by unique mechanisms 
specific to reovirus.  Our study suggests that the mediators involved may provide novel insight 
into the processes involved in airway remodeling disease and provide possible therapeutic 
answers. 
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